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Aims of the study 
The overall aim of the work described in this thesis was to obtain deeper insight into the 
molecular mechanisms underlying disease progression in follicular lymphoma (FL), to identify 
markers for prediction of transformation and survival in FL, and to assess the effect of existing 
treatments and generate hypotheses for new therapeutic targets. More specifically: 
x In Paper 1, we aimed to characterize the frequency and pattern of secondary 
chromosomal aberrations in t(14;18)(q32;q21)-carrying non-Hodgkin's lymphoma and 
relate this to morphological subtypes and clinical outcome.  
 
x In Paper 2, we aimed to assess the effect of high-dose chemotherapy with autologous 
stem cell transplantation (HD-ASCT) in patients with transformation of indolent B-cell 
lymphoma, and a prospective national multi-center study was performed for this 
purpose. In this paper, we further sought to assess the effect of in vitro purging of stem 
cell grafts on patient survival following HD-ASCT with ASCT. 
 
x In Paper 3, we aimed to further investigate the role of genomic aberrations in FL and to 
shed light on clonal evolution in disease relapse and progression. For this purpose, a 
genome-wide investigation of DNA copy number alterations in serial biopsies of FL was 
performed, and the relation to clinical parameters was investigated. 
 
x In Paper 4, we aimed to identify gene signatures and signaling pathways of significance 
for the progression and transformation of FL. For this purpose, a whole-genome 
integrative analysis of DNA copy number and gene expression data from serial FL 
biopsies in patients with and without transformation was performed. 
   
  
11 
 
General introduction 
Cancer is a major health problem worldwide and increasing incidence rates has been the trend 
in developed countries for decades. According to WHO and the GLOBOCAN project 
(http://globocan.iarc.fr/) the incidence of cancer was 12.6 million and the mortality exceeded 
7.6 million in 2008. Cancer has for long been considered a health problem related to lifestyle 
and mainly affecting the elderly population. As the treatments for several cancer types have 
improved, the number of people who have recovered from or live with cancer increases and 
late effects of cancer treatment affect life quality and employability of a considerable number of 
people. According to the Norwegian Cancer Registry there were 28 271 new cancer cases in 
Norway in 2010 and the incidence rate has increased steadily since the registration started in 
1951. Then again, the incidence rates of colon cancer, lung cancer, bladder cancer and breast 
cancer show trends for decreasing rates during the last five year period, possibly reflecting an 
effect of preventing measures. In the less developed parts of the world, the incidence of cancer 
increase as communicable diseases are better controlled. Although the incidence is lower, the 
relative mortality and morbidity of cancer is much higher in less developed countries due to 
delay (or lack of) diagnosis and limited availability of treatment and palliative care.  
The four main categories of cancer diseases are the carcinomas arising from cells 
covering bodily surfaces, the sarcomas arising from connective tissue, muscle and bone, the 
tumors of the central nervous system and the hematological malignancies. The latter comprise a 
heterogeneous group of leukemias, myelomas and lymphomas. The lymphomas are divided into 
Hodgkin’s and the non-Hodgkin’s lymphomas which are further subdivided into several specific 
disease entities. The main focus of this thesis is follicular lymphomas, one of the most common 
types of non-Hodgkin’s lymphoma.  
Common characteristics of cancers 
Cancer results from a multi-step process in which various genetic mutations accumulate over 
time and confer growth advantages to a cell. The development of a tumor has many parallels to 
the Darwinian evolution of species; randomly acquired mutations endow cells with new 
properties, and natural selection favors the expansion of cell clones that achieve growth 
advantages within the surrounding microenvironment. The incidence of cancer increases with 
age, consistent with a multi-step accumulation of mutations over many years underlying 
malignant transformation. The rare cases of childhood cancer are more often associated with 
germline mutations, consistent with the need for fewer somatic mutational steps and shorter 
time to malignant transformation. 
Cancer cells are endowed with a set of fitness traits that constitutes “The hallmarks of 
Cancer”, as reviewed by D. Hanahan and R.A. Weinberg in 2000 and 2011 and listed in Figure 1 
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(Hanahan & Weinberg, 2000;Hanahan & Weinberg, 2011). The exact molecular mechanisms 
underpinning each of the hallmark properties vary between cancer types and even between 
individual cancers of the same type. Each property may be acquired at different time points of 
cancer evolution (Vogelstein et al, 2013). The molecular pathways leading to cancer are 
heterogeneous; single oncogenes may influence several signaling pathways that in turn enable 
several of the hallmarks. 
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Insensitivity to anti-growth signals
1)
4)
2)
3)
5)
Self-sufficiency in growth signals
6)
9)
7)
8)
10)
Evasion apoptosis
Limitless replicative potential
Tissue invasion and metastasis
Sustained angiogenesis
Deregulating cellular energetic
Avoiding immune destruction
Tumor-promoting inflammation
Genetic instability
Common characteristics of cancer
Figure 1. Common characteristics of cancer. 1) Cancer cells may attain aberrant secretion of growth-factors 
acting in autocrine loops or engage stromal cells and cells of the innate immunity in paracrine growth factor 
loops. Activating mutations in growth factor receptors or intracellular signaling molecules may fuel cancer cell 
growth and proliferation. 2) Molecules that normally block cell cycle progression or stimulate terminal 
differentiation of cells may be inactivated to make the cancer cells insensitive to anti-growth signals. 3) Loss of 
pro-apoptotic regulators (e.g p53), inactivation of apoptose effector molecules or increased anti-apoptotic 
signaling in the cancer cell enable evasion of apoptois and inhibit DNA repair. 4) The natural shortening of 
chromsomal endings (telomeres) in each round of cell division is avoided by activation of telomerase, an 
enzyme that maintains the telomers and contributes to limitless replicative potential of a cancer cell. 5) As a 
tumor expands beyond 1-2 cubic millimeters hypoxia limits its growth. Both cancer cells and tumor infiltrating 
immune cells stimulate formation of a new vascular tree by disrupting the balance between angiogenetic 
inducers and inhibitors. 6) Cancer cells may attain the ability to migrate and invade into surrounding tissue, 
enter lymphatic vessels or the bloodstream and settle at distant sites forming metastases. 7) Tumors often 
show high rates of glycolysis and lactate production in the presence of oxygen (aerobic glycolysis, the Warburg 
effect). Lactate dehydrogenase facilitates glycolysis in the lack of oxygen. Lactate produced in hypoxic areas of 
a tumor can and fuel oxidative fosforylation in oxygenated tumor regions (ref Bayley and Devilee 2012) 8-9) 
Even though cancer cells deviate profoundly in behavior and phenotype from normal cells, they escape 
detection and destruction by the immune system. This is accomplished by secretion of immunomodulatory 
compounds and recruitment of immunosuppressive cells. In addition, the tumor infiltrating T-cells, B-cells, NK-
cells and macrophages create a tumor promoting inflammatory environment. 10) Genetic instability in tumor 
cells results in an increased mutational rate and acquisition of genomic aberrations which endow tumor cells 
with new properties and contribute to tumor progression. 
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Two major categories of genes are involved in cancer development. Oncogenes with gain 
of function promote tumor growth, while tumor suppressor genes promote tumor growth by 
loss of function. Oncogenes are activated by various mutational events targeting one allele and 
act dominantly. Tumor suppressor genes are recessive and inactivation requires mutations 
targeting both alleles.  
Aberrant expression of oncogenes and tumor suppressor genes is achieved by a variety 
of genetic and epigenetic changes. Mutations at the nucleotide or base pair level, gain or loss of 
genomic DNA, chromosomal rearrangements such as translocations, insertions and inversions, 
hyper-or hypomethylation of genes and alterations in chromatin structure may all lead to 
altered expression or altered activity of the targeted gene and its protein product (Vaux et al, 
1988;Slamon et al, 1987;Symonds et al, 1994;Kinzler & Vogelstein, 1996;Lengauer et al, 
1998;Hanahan & Weinberg, 2000;Hanahan & Weinberg, 2011;Suva et al, 2013). In addition, 
alternative splicing of mRNA and post-translational protein modifications may also contribute to 
increased or decreased function of proteins (Maciejewski & Padgett, 2012;McCabe et al, 2012). 
During the last decade we have gained knowledge about the regulatory role of microRNAs in 
transcription and translation, and there is evidence for a role of altered microRNA expression in 
carcinogenesis (He et al, 2005;Lovat et al, 2011;Landau & Slack, 2011).  
The recognition and repair of DNA damage is attenuated in cancer. The mechanisms for 
DNA repair and accurate chromosomal segregation at cell division may be overridden by the 
high proliferation rate and loss of normal cell cycle control. The genes governing chromosomal 
integrity, DNA replication and repair may also themselves be targeted by inactivating mutations 
or epigenetic silencing, resulting in an increased mutational rate and genomic instability (Lord & 
Ashworth, 2012). The various genetic aberrations observed in cancer cells and the aberrations 
observed at the genomic level in particular, collectively reflect the degree of genomic instability. 
Genomic instability contributes to genetic diversity among the tumor cells and cells with 
improved fitness establish new clones leading to disease progression. This is reflected on the 
clinical level, as a high degree of genomic instability correlates to worse prognosis in several 
cancer types (Russnes et al, 2010;Walther et al, 2008;Pretorius et al, 2009;Bakhoum et al, 
2011).  
At the chromosomal level the degree of genomic instability can be determined by 
quantifying the number of chromosomal translocations and other balanced rearrangements 
(inversions, insertions), the number of genomic gains and losses (amplifications and homo- and 
heterozygous deletions, respectively) and acquired uniparental disomies (in which one parental 
allele is lost while the other parental allele is duplicated). 
Screening of cancer genomes by deep sequencing has shown that individual cancers may 
contain thousands of mutations, of which the majority is not essential for tumor progression 
(Vogelstein et al, 2013). The driver mutations provide the necessary traits to overcome intrinsic 
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control mechanisms and constraints in the microenvironment and are thus selectively 
advantageous. Passenger mutations may result from the same mutational mechanisms, but do 
not contribute to expansion of the tumor and are selectively neutral (e.g. mutations in protein 
coding genomic regions that do not lead to a change of aminoacid or mutations targeting genes 
that are usually not transcribed in tumor cells such as hemoglobin, albumin or collagen in 
carcinoma cells). 
Development of phenotypic and genotypic heterogeneity during clonal expansion of 
tumor cells has been well documented in adenocarcinoma of the colon, in which the various 
mutated genes promoting progression from benign adenoma to invasive carcinoma have been 
characterized (Vogelstein et al, 2013;Hanahan & Weinberg, 2000). The high prevalence of 
premalignant clonal expansions (adenomas, dysplasia, expansions of atypical cells etc) 
compared to cancer rates indicate that microenvironmental and immunological factors naturally 
constrain tumor growth (Greaves & Maley, 2012).  
In addition to cancer cells, neoplastic lesions contain various amounts of immune 
inflammatory cells, endothelial cells, pericytes, fibroblasts, tissue stem cells and progenitor cells. 
The composition of the tumor microenvironment is associated with prognosis for many cancer 
types, indicating a crucial role for tumor growth, progression and metastasis. On the one hand, 
tumor development and progression may be constrained by the immune system. For instance, 
genetically engineered mice lacking B- and T-lymphocytes (RAG2-deficient mice), showed 
enhanced development of various cancers. The finding indicated a role for lymphocytes in 
preventing cancer. Furthermore, the incidence of lymphomas and some solid tumors is 
increased in immunosuppressed patients. More compelling, infiltration of cytotoxic T-cells and 
NK-cells is associated with improved outcome in colon, lung and ovarian cancer as well as in 
lymphomas, indicating an anti-tumor immune response (Grivennikov et al, 2010). Tumor 
infiltrating B-and T-lymphocytes may recognize tumor antigens, and immune responses against 
cancer can be induced and give long-lasting remissions (Motz & Coukos, 2013).   
Then again, cancer cells employ various mechanisms to avoid detection and destruction 
by the immune system. The expression of MHC class I is often low in cancer cells, preventing 
presentation of tumor antigens to antigen presenting cells (Motz & Coukos, 2013). Cancer cells 
often secrete immunosuppressive factors or immune-modulatory comƉŽƵŶĚƐ ƐƵĐŚ ĂƐ d'&ɴ 
(Lippitz, 2013). Furthermore, by secreting chemokines, cancer cells may recruit 
immunosuppressive cells, such as T-regulatory cells and myeloid-derived suppressor cells into 
the tumor microenvironment. A high content of tumor associated macrophages (TAMs) 
correlates with inferior outcome in several cancer types, indicating a key role for TAMs in 
promoting tumor growth and progression (Grivennikov et al, 2010). Furthermore, certain types 
of chronic inflammation predispose for cancer development, exemplified by the increased risk 
for colon cancer in patients with inflammatory bowel disease. In an established tumor, the 
immune cells and stromal cells are engaged in a complex interplay with the tumor cells, and 
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their reciprocal signaling creates a microenvironment in favor of tumor expansion. The stromal 
and inflammatory cells provide growth factors and survival factors fueling tumor growth. They 
secrete enzymes that influence the extracellular matrix and facilitate invasion of tumor cells in 
neighboring tissue and promote metastasis to distant sides. Expression of angiogenic factors 
such as VEGF and FGF by tumor cells or angiogenic signals produced by TAMs promotes 
aberrant vascularization of the tumor.   In addition, TAMs promote the release of reactive 
oxygen species (ROS) with mutagenic effect both in tumor cells and in the stromal cells 
(Hanahan & Weinberg, 2000;Hanahan & Weinberg, 2011;Greaves & Maley, 2012;Lippitz, 
2013;Grivennikov et al, 2010). In summary, the cellular composition and the cytokine profile of 
the tumor microenvironment may tip the balance either in favor of anti-tumor immunity or in 
favor of tumor progression. Various treatment strategies targeting the tumor microenvironment 
have been developed during the last decades, for a review see for instance G. Motz and G. 
Coukous 2013 (Motz & Coukos, 2013).   
In lymphomas, the microenvironment also plays a complex role in tumor development 
and progression (Dave et al, 2004;Lenz et al, 2008b;Cardesa-Salzmann et al, 2011;de Jong & 
Fest, 2011). For follicular lymphoma, this will be briefly discussed in sections below. For more 
detailed reviews of the impact of the microenvironment in lymphomas, see for instance J.G 
Gribben 2010 and P. Amé-Thomas 2013 for follicular lymphoma and Y. Liu 2013 for Hodgkin’s 
lymphoma (Gribben, 2010;Ame-Thomas & Tarte, 2013;Liu et al, 2013). The lymphomas 
recapture features of their normal counterparts; B- and T-lymphomcytes. In the malignant 
transformation, the mechanisms governing normal lymphocyte development and activation are 
subverted to promote tumor growth. Thus, the molecular mechanisms regulating normal 
lymphocyte development and differentiation are important keys to the understanding of 
lymphomagenesis. 
The immune system 
The immune system has evolved to provide protection against disease-causing microorganisms. 
Demonstrating its importance for survival, an innate immune system is present in species at 
almost every level of phylogenesis (Cooper & Herrin, 2010). Innate immunity provides the rapid, 
first line defense against a diversity of invading viruses, bacteria, fungi and parasites. The 
adaptive immune system, present in vertebrates, provides a highly specific secondary line of 
defense and involves the generation of immunological memory (Cooper & Herrin, 2010). 
Innate immunity 
The innate immune system is composed of both specialized cells (phagocytes) and humoral 
effector molecules (complement system). Phagocytes recognize, engulf and digest pathogenic 
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microorganisms. The complement system interacts with microorganisms to directly kill them as 
well as to promote phagocytosis. The early innate immune response is evoked by the 
recognition of a pathogen by receptors on the cell surface of macrophages residing in the skin 
and mucosa. These receptors, termed pattern recognition receptors (PRRs), are germ line 
encoded and constitute a limited repertoire of sensors for pathogenic molecular patterns. 
Signaling PRRs activates macrophages to engulf (phagocytosis) and kill pathogens as well as to 
secrete inflammatory cytokines and chemokines. Inflammation of an infected or damaged tissue 
in turn leads to recruitment of the phagocytic neutrophil granulocytes and antimicrobial 
proteins such as the complement factors. The inflammatory response serves to deliver effector 
molecules and cells to the site of infection, to prevent further spread of infection by coagulation 
in microvasculature and to promote tissue repair.  
Like the macrophages, dendritic cells residing in peripheral tissues constantly sample 
their microenvironment and become activated by the binding of a pathogen to PRRs. Engulfed 
pathogens are processed and presented to the cells of the adaptive immune system, and 
dendritic cells are crucial for the triggering and shaping of the following antigen-specific 
response (Janeway CA, 2005). 
Adaptive immunity 
The effector cells of the adaptive immune system are the B-and T-lymphocytes. Activation of B- 
and T-cells depends on a complex interplay with antigen presenting cells, such as dendritic cells, 
and results in a highly specific and flexible immune response. The B- and T-cells carry surface 
receptors with a broad repertoire of antigen specificities, enabling the recognition of any 
potential pathogen (Bonilla & Oettgen, 2010;Cooper & Herrin, 2010). The variable regions of B-
and T-cell antigen receptors are encoded in gene clusters containing multiple gene segments. 
During B-and T-cell development these gene segments are cut and spliced in a myriad of 
combinations, introducing combinatorial diversity in the repertoire of antigen receptors. 
Additional variability is achieved by the introduction of random mutations in the splice regions 
between the recombined gene segments (mutational diversity). Each B- and T-cell are thus 
equipped with receptors with unique antigen specificity.  
Activated B-lymphocytes differentiate into antibody secreting plasma cells providing 
humoral immunity mainly against extracellular pathogens/antigens. Activated T-lymphocytes 
regulates cellular immunity by the action of different T-cell subsets. Subset of CD4 positive T-
cells may either support B-lymphocyte differentiation or stimulate macrophages and the subset 
of CD8 positive cytotoxic T-cells which recognize and kill cells infected by intracellular 
pathogens.    
Following the initial immune response, immunological memory is established by the 
long-term survival of B- and T-lymphocytes carrying antigen-specific receptors (Bonilla & 
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Oettgen, 2010). These memory B- and T-cells are able to elicit a more rapid and efficient 
immune response to the pathogen at a second encounter.  
The lymphatic system, composed of the lymphoid organs, provides the environment for 
lymphocyte development and activation (Bonilla & Oettgen, 2010). B- and T-lymphocytes 
originate from haematopoietic precursors in the bone marrow and develop in the primary 
lymphoid organs; the bone marrow and thymus, respectively. Supported by stromal cells of the 
primary lymphoid organs, lymphocytes that produce functional antigen receptors mature, while 
those with self-reactive receptors are eliminated. Thus, development of autoimmunity is 
avoided (Janeway CA, 2005). Mature B- and T-cells circulate in the peripheral blood and 
populate the secondary lymphoid organs; the lymph nodes, mucosa associated lymphatic tissue 
(MALT) and spleen. Antigens from peripheral tissues are drained into the lymphatic fluid and 
travel to the lymph nodes or MALT, while antigens entering the blood are captured in the 
spleen. Under the influence of signals from the innate immune system, a finely tuned humoral 
and cellular immune response is raised by the B- and T-cells, respectively. Antibody secreting 
plasmacells developed from B-cells migrate to the bone marrow or lamina propria of mucosa, 
while activated T-cells may travel to the sites of infection to kill pathogens or activate 
macrophages (Janeway CA, 2005;Bonilla & Oettgen, 2010).   
B-cell development and assembly of the B-cell receptor 
B-lymphocytes are derived from common lymphocyte progenitor cells in the bone marrow 
(BM), and commitment to B-cell lineage is controlled by a set of transcription factors including 
PU.1, IKAROS, E2A, EBF, PAX5 and IRF8 (Janeway CA, 2005;LeBien & Tedder, 2008;Bonilla & 
Oettgen, 2010). In the progenitor B-cell (pro-B cell) the assembly of the B-cell receptor (BCR) is 
initiated by recombination of the immunoglobulin (Ig) gene segments. First, the 
immunoglobulin heavy chain (IgH) is assembled by recombination of gene segments from four 
regions on chromosome 14: The variable region (V) containing 51 segments, the diversity region 
(D) containing 27 segments, the joining region (J) containing 6 segments and one constant ;ʅͿ
region (Figure 2). The recombination of Ig gene segments is mediated by the enzyme complex 
RAG1/RAG2 which introduces DNA double strand breaks between the respective gene 
segments. One randomly picked gene segment from each of the regions V, D and J are then 
joined by the DNA repair mechanism termed non-homologous end-joining. The resulting 
combination of gene segments is unique for each developing B-cell. Following transcription and 
translation, the variable region of the Ig heavy chain (IgVH) is formed and eventually makes part 
of the antigen recognition site of the BCR. Antigen receptor diversity is also obtained by the 
action of the enzyme TdT, which randomly adds or deletes nucleotides (N-nucleotides) in the 
junctions between the recombined gene segments. If recombination results in the production of 
a functional IgH that is expressed on the cell surface, the B-cell receives stimulatory signals and 
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continues to the pre-B stage. At this stage a surrogate light chain is transcribed from the two 
genes sƉƌĞ ĂŶĚ ʄϱ and expressed together with the IgH, thus forming a pre-B cell receptor 
(Janeway CA, 2005;LeBien & Tedder, 2008). 
In pre-B cells the immunoglobulin light chains (IgL) are assembled from any one of two 
ŐĞŶĞůŽĐŝ͖ƚŚĞʃ-locus on chromosome 2 or ƚŚĞʄ-locus on chromosome 22. A recombination of 
ƚŚĞʃ-gene is first attempted by splicing one of 31-35 V segments with one of 5 J segments and 
ƚŚĞƐĞŐŵĞŶƚ͘/ĨƚŚŝƐĨĂŝůƐƚŽƉƌŽĚƵĐĞĂůŝŐŚƚĐŚĂŝŶ͕ƚŚĞʄ-gene (containing 29-33 V segments, 4-5 
J segments and one C segment) undergoes the same process. Upon successful assembly, two 
light chains are combined with two heavy chains in a heterotetramer and a complete IgM-
molecule is expressed on the surface of the immature B cell. Interaction with self-molecules 
present in the bone marrow environment then determines the fate of the immature 
lymphocyte. B-cells expressing IgM with the capacity to bind self-molecules are eliminated by 
apoptosis, while non-self-reacting cells receive signals for survival and maturation. The 
rearrangement of BCR gene loci combined with the negative selection of auto-reactive B-cells 
results in mature, circulating B-cells with a tremendous repertoire of BCR-specificities and the 
capacity to recognize almost any foreign antigen. The mature, naïve B-cells expressing both 
surface IgM and IgD then leave the BM to circulate in the peripheral blood, primary follicles and 
the follicle mantle zones of the lymph nodes and MALT (Janeway CA, 2005;LeBien & Tedder, 
2008).  
In addition to the different steps in BCR-assembly, the individual stages of B-cell 
development are characterized by differential expression of surface markers and intracellular 
markers representing i.e. the growth factor receptors, cytokine receptors and co-receptors, 
signal transducing molecules, enzymes and transcription factors. For instance, surface 
expression of CD38 characterize the pro-B and pre-B cells in the BM as well as the fully 
diffentiated plasma cell. The classical B-cell markers CD19 and CD20 are expressed from the late 
pro-B stage and through all stages of B-cell life, until they are lost in the terminal differentiation 
of plasma cells. The expression of lymphocyte markers can be detected by various laboratory 
methods such as Western blotting, immunohistochemical staining, flowcytometry with 
immunostaining and real time PCR and gene expression analyses (Hystad et al, 2007;Shaffer et 
al, 2001) and is used for both diagnostic and research purposes to distinguish developmental 
and differential stages of lymphocytes. 
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Figure 2. The IGH gene cluster is located on chromosome 14q32 and contains about 40 V-
segments, 25 D-segments and six J-segments as shown on the figure. In B-cell development 
somatic recombination of one randomly picked V, D and J segment takes place. In addition, 
the IGH locus contains a large cluster of C genes encoding the constant regions of the 
immunoglobulin protein that determines the antibody isotype. CDR1-3 (complementarity-
determining regions 1-3) represent the hypervariable regions of the immunoglobulin 
transcript. These are flanked by FR1-4 (framework regions 1-4) which show less sequence 
variability. 
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T-cell development 
Common lymphocyte precursor cells originating from the bone marrow populate the thymus 
and start differentiation and proliferation under the influence of IL-1, IL-7 and TNF. 
Commitment to the T-cell lineage is controlled by the transcription factor Notch-1 among 
others, which induce expression of genes regulating T-cell receptor (TCR) assembly (Bonilla & 
Oettgen, 2010). In the thymic cortex the immature T-cells express TdT and carry out 
rearrangement of TRC-genes in a manner similar to the BCR assembly in B-cell development. 
dŚĞdZŽĨƚŚĞɲɴd-ĐĞůůƐĂƌĞĂƐƐĞŵďůĞĚĨƌŽŵɲ- ĂŶĚɴ-chain loci (gene names TCA@ and TRB@) 
on chromosome 14 and 7, respectively. The immature T-cells express the membranous markers 
CD1a, CD3, CD5 and CD7. As they move towards the thymic medulla, maturing T-cells express 
TCR in complex with CD3 and they are double positive for CD4 and CD8. Thymic epithelial cells 
express both MHC class I and MCH class II molecules presenting self-peptides to the maturing T-
cells. Low avidity binding to the complexes of MHC and self-peptide leads to positive selection 
of the maturing T-cells. T-cells with low avidity binding to MHC I become CD8+ single positive. T-
cells with low avidity binding to MCH II become CD4+ positive (Bonilla & Oettgen, 2010). No 
binding and high avidity binding of the TCR to complexes of MHC and self-antigen result in 
elimination of the T-cell. Thus, development of functional T-cells without self-reactivity is 
secured (Janeway CA, 2005).  
The production of mature T-cells mainly takes place during embryonic development and 
childhood. After puberty the thymus atrophies. In adulthood, the population of T-cells is 
maintained by long-lived T-cells, division of mature T-cells and a low production of new T-cells. 
The mature T-cells recirculate in the blood and secondary lymphoid organs. The CD8 positive T-
cells can recognize peptides from intracellular pathogens bound to MHC class I molecules of 
tissue cells. This triggers activation and differentiation into cytotoxic effector T-cells which 
efficiently kill the infected tissue cell. The CD4 positive T-cells, or T-helper cells, can recognize 
peptides bound to MHC class II molecules. These peptides originate either from pathogens in 
intracellular vesicles of macrophages and dendritic cells or from extracellular bacteria and toxins 
ingested and processed by antigen presenting cells. Depending on the type of antigen the T 
helper cells elicit either a cellular immune response by activating macrophages (T helper 1 cells; 
Th1 cells) or a humoral immune response by activating B-cells (T helper 2 cells; Th2 cells). The 
Th1 secrete INF-ɶǁŚŝĐŚƚƌŝŐŐĞƌ ŝŶĨĞĐƚĞĚŵĂĐƌŽƉŚĂŐĞƐƚŽĚĞƐƚƌŽǇŝŶƚƌĂĐĞůůƵůĂƌŵŝĐƌŽŽƌŐĂŶŝƐŵƐ͕
while the Th2 cells secrete B-cell growth factors such as IL-4 and IL-5.  
In addition to the cytotoxic T-cells and T-helper cells there are other subsets of T-cells 
with more specialized functions and limited distribution. The Follicular T-helper cells (FTH) 
reside in lymph nodes and the spleen where they take part in B-cell activation and formation of 
the germinal center. They express Bcl6 and CD10 as the germinal center B-cells, in addition to 
CD4, CD57 and PD-1. FTHs produce the chemokine CXCL13 causing induction and proliferation 
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of follicular dendritic cells (FDCs), which in turn express CXCR5 (receptor for CXCL13) facilitating 
the migration of B- and T-cells into the germinal center.  
The T-regulatory-cells (Tregs; CD4 and CD25 positive T-cells) arise in the thymus. A 
stronger binding of CD4 positive T-cells to a complex of self-derived peptides and MHC class II 
molecules induces expression of FOXP3. This gene encodes a transcription factor which directs 
differentiation of the T-cell into a T regulatory cell. Tregs are able to inhibit activated T- and B-
cell as well as antigen presenting cells and can thus shut off or suppress immune responses. The 
Tregs are important for limitations of autoimmune responses and prevention of autoimmune 
diseases. In cancer, Tregs can suppress immune responses to tumor and thus promote tumor 
growth. As previously mentioned, the infiltration of Tregs in the tumor is associated with poor 
prognosis in several types of cancer (Janeway CA, 2005;Bonilla & Oettgen, 2010). 
Subsets of both B- and T-cells possess antigen receptors of limited diversity. The B-1 cells 
carry the surface marker CD5, proliferate in and populate the peritoneal and pleural cavities, 
and react mainly to polysaccharide antigens (certain bacteria). They generate IgM 
independently of helper T-cells and do not produce immunological memory (LeBien & Tedder, 
2008)͘ dŚĞdZŽĨ ƚŚĞɶɷd-ĐĞůůƐŽƌŝŐŝŶĂƚĞ ĨƌŽŵɶ- ĂŶĚɷ-chain loci on chromosome 7 and 14, 
ƌĞƐƉĞĐƚŝǀĞůǇ͘ dŚĞ ɶɷ d-cells do not recycle in secondary lymphoid organs, but populate the 
gastrointestinal epithelium and skin. They express TCRs of limited diversity and recognize 
antigen presented by non-classical MHC-molecules in the CD1-family. The B-ϭ ĐĞůůƐ ĂŶĚ ɶɷ d-
cells are often referred to as “innate-like lymphocytes” (Janeway CA, 2005).  
Activation and differentiation of B-cells  
The activation and differentiation of B-cells result in production of antigen specific antibodies 
that can neutralize pathogens or mark (opsonize) them for phagocytosis or complement 
binding. Circulating, naïve B-cells encounter antigens as they pass through the secondary 
lymphoid organs (Natkunam, 2007;Bonilla & Oettgen, 2010). The antigen-induced activation of 
B-cells which takes place in the specialized environment of the lymph node (Figure 3), spleen or 
MALT is termed the germinal center reaction.  
The first signal for B-cell activation is cross-linkage of two surface B-cell receptors (BCRs) 
by antigen binding. The majority of antibody responses are T-cell dependent and co-stimulatory 
signals for B-cell activation are delivered by antigen-specific T helper-cells. The complex of 
antigen bound to BCR is internalized and processed so that antigen peptides can be exposed on 
MHC class II molecules on the surface of the B-cell. Thus, B-cells can act as antigen-presenting 
cells for T-helper cells engaging them in reciprocal activation. Activated T helper-cells express 
CD40 ligand (CD154) that directly engages CD40 on B-cells. CD40 belongs to the TNF-receptor 
family and downstream signaling promotes B-cell growth and immunoglobuline class-switching. 
The T-helper cells also secrete cytokines such as IL-4 which induces B-cell proliferation. The B-
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cells migrate from the T-cell zone into the primary follicle where they populate the follicular 
dendritic cell (FDC) meshwork, proliferate and form a secondary follicle (Figure 3 and 4). Resting 
naïve B-cells without specificity for the present antigen are displaced to the mantle zone of the 
follicle.  
 
 
 
 
 
 
 
The dark zone of the secondary follicle is packed with centroblasts (Figure 4). These are 
rapidly dividing B-cells undergoing somatic hypermutation (SHM) of the variable regions of the 
BCR gene loci; detailed below. In the central light zone B-cells with mutated BCRs convert to the 
smaller non-dividing centrocytes and intermingle the FDC, the follicular T-helper cells and 
macrophages. B-cells expressing BCRs with high affinity for antigens bound to the surface of 
FDCs receive survival signals, while B-cells attaining low-affinity BCRs following SHM are 
eliminated by apoptosis and engulfed by the follicular macropghages. The cytokines produced 
by antigen specific T-helper cells stimulate Ig class-switch recombination; detailed below. 
Figure 3. The architecture of a lymph node (Immunobiology 6
th
 edition. Janeway, Travers, 
Walport, Shlomchic. Garland Science 2005). Naïve B-cells enter the lymph node through the 
high endothelial venules in the medullary cords. B-cells that bind antigen become activated at 
the border between the T-cell (blue) and the B-cell (yellow) areas. Activated B-cells then 
migrate into a primary follicle, proliferate and form a germinal center.
24 
 
Ultimately the antigen specific B-cells differentiate into plasma cells or memory B-cells that 
leave the germinal center (Janeway CA, 2005;Natkunam, 2007;Swerdlow SH, 2008). 
Certain antigens activate naïve B-cells in the absence of T helper-cells. Bacterial 
polysaccharides are made up of repetitive structures which can cause extensive cross-binding of 
BCRs on the B-cell surface and thus provide a strong signal for activation. Other antigens, such 
as bacterial lipopolysaccharide (LPS) bind both to BCRs and Toll-like receptors expressed on B-
cells providing co-stimulatory signals for B-cell proliferation (McGettrick & O'Neill, 2007). 
In centroblasts, the variable regions of heavy and light chain Ig genes (IgVH and 
IgVKappa or IgVLamda) are subject to somatic hypermutation (SHM). The process of SHM is 
induced by action of BCL6 which functions as a transcriptional repressor. BCL6 repress 
transcription of TP53 and other genes regulating the DNA-damage response. The attenuated 
DNA-damage response then allows DNA double strand breaks which are necessary for SHM.  
During SHM the enzyme AID deaminates cytosine residues to uracil in the variable 
regions of the Ig genes. The base excision repair or mis-match repair pathways are then 
triggered to replace uracil. Simultaneous DNA replication by error-prone polymerases 
introduces mutations. The resulting characteristic pattern of mutations leads to diversification 
of the Ig gene sequences and thus an altered configuration of the antigen binding site of the 
BCR (Natkunam, 2007;Klein & la-Favera, 2008;LeBien & Tedder, 2008).  
Following SHM the B-cells are prone to apoptosis as expression of the anti-apoptotic 
BCL-2 pƌŽƚĞŝŶ ŝƐ ƐŚƵƚ ĚŽǁŶ ĂŶĚ ƚŚĞ E&ʃ ƉĂƚŚǁĂǇ ŝƐ ŝŶĂĐƚŝǀĞ͘ KŶůǇ -cells with high affinity 
binding of surface BCR to antigen are rescued from apoptosis and re-express Bcl2, while cells 
with low affinity BCR undergo apoptosis and are engulfed by the germinal center macrophages. 
The early primary immune response is characterized by the secretion of IgM antibodies with low 
antigen affinity. B-cells selected for further differentiation undergo class switch directed by 
cytokines and co-stimulatory signals provided by the T helper cells and FDCs present in the 
microenvironment. In class switch the rearranged and hypermutated IgVH gene is joined to a 
new constant C-region. Thus, the isotype of the produced immunoglobuline molecule is 
switched from IgM to IgG, IgA or IgE. There are nine classes of heavy chains; IgM, IgD, IgA1-2, 
IgG1-4, IgE with various ability to neutralize or opsonize pathogens and to activate the 
complement system. The combination of cytokines and co-stimulatory signals provided by FDCs 
and Th2- or Th1-cells determines the antibody class which is tailored for the type of antigen to 
be eliminated (Klein & la-Favera, 2008). Most commonly, high affinity IgG and IgA are produced 
which characterize the late primary and secondary immune responses. Interaction of B-cells 
with FDC through CD23 and CD40 ligand binding, leads to expression of the transcription factor 
IRF4/MUM1 and down regulation of Bcl-6 in the activated B-cells. This initiates terminal 
differentiation into plasma cells (Figure 4). Plasma cells enter the peripheral blood and home to 
BM or the mucosa of the digestive tract.  The cytoplasm usually contains IgG or IgA, repectively, 
and there is no longer surface expression of immunoglobuline/BCR. Some become long lived 
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plasma cells in BM niches, contributing to humoral immunological memory (Janeway CA, 
2005;LeBien & Tedder, 2008). 
Following the germinal center reaction, some of the activated B-cells differentiate into 
long-lived memory B-cells (Figure 4). Memory B-cells express BCRs with somatically 
hypermutated antigen binding sites and IgG, IgA or IgE heavy-chains. They circulate in 
peripheral blood and populate follicular marginal zones in lymph nodes, spleen and MALT. Post 
germinal center memory B-cells  tend to home to the sites where they first encountered 
antigen; B-cells arising from MALT return there and B-cells arising from lymph nodes return to 
nodes and BM (Janeway CA, 2005;Heyzer-Williams & Heyzer-Williams, 2005;Kalia et al, 2006). 
 
 
 
 
 
  
Figure 4. The germinal center reaction. Detailed in the main text.
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BCR signaling 
The BCR of a naïve B-cell is constrƵĐƚĞĚŽĨŵĞŵďƌĂŶĞďŽƵŶĚ/ŐDůŝŶŬĞĚƚŽ /ŐɲĂŶĚ /ŐɴĐŚĂŝŶƐ
(CD79a and CD79b). IgM recognizes and binds antigen on the B-ĐĞůůƐƵƌĨĂĐĞ͕ǁŚŝůĞ/ŐɲĂŶĚ/Őɴ
initiate the intracellular signaling cascade which ultimately results in the differentiation of the B-
cell into an antibody producing plasma cell or memory cell. The signaling units of the BCR, the 
/ŐɲĂŶĚ/ŐɴĐŚĂŝŶƐ͕ŚĂǀĞƚǇƌŽƐŝŶƌĞƐŝĚƵĞƐŽŶƚŚĞŝƌĐǇƚŽƉůĂƐŵĂƚŝĐƚĂŝůƐ;ŝŵŵƵŶŽƌĞĐĞƉƚŽƌƚǇƌŽƐŝŶĞ-
based activation motifs = ITAMs). Cross linking of surface IgMs by antigen binding leads to 
phosphorylation of these tyrosin residues by Src family kinases (Fyn, Blk, Lyn in B-cells).  Syk 
tyrosin kinase recognizes and binds to these phosphorylated tyrosines and activates 
downstream intracellular targets: (i) Activation of phospholipase C (PLC-ɶͿ ǀŝĂ ƚŚĞ ĂĚĂƉƚŽƌ
protein BLNK and recruitment of Bruton tyrosin kinase (Btk). PLC-ɶĐůĞĂǀĞƐW/ϮW ŝŶƚŽ'ĂŶĚ
W/ϯǁŚŝĐŚŝŶƚƵƌŶƌĞƐƵůƚƐŝŶĂĐƚŝǀĂƚŝŽŶŽĨƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌƐE&ʃǀŝĂWƌŽƚĞŝŶŬŝŶĂƐĞ;W<Ϳ
and NFAT via Calcineurin, respectively. (ii) Binding of GEFs (guanine-nucleotide exchange 
factors) to the receptor complex activates small G-proteins (Ras and Rac) and downstream 
MAPkinase cascades. This finally activates the transcription factor JUN (Janeway CA, 
2005;Kurosaki et al, 2010) (Figure 5).  
At least three surface molecules are closely associated with the BCR. CD21 binds 
antigens tagged with the complement fragment C3d and cluster with BCR and CD19 and CD81. 
The cytoplasmatic tail of CD19 is then phosphorylated enabling it to bind Src family kinases and 
recruit PI 3-kinase. The co-receptor complex CD19/CD21/CD81 enhances BCR-signaling many-
fold. 
dŚĞ ƚĂƌŐĞƚ ŐĞŶĞƐ ŽĨ E&ʃ͕ E&d ĂŶĚ :hE ĐŽůůĞĐƚŝǀĞůǇ ƉƌĞǀĞŶƚ ĂƉŽƉƚŽƐŝƐ͕ ƐƚŝŵƵůĂƚĞ
proliferation and initiate the differentiation of B-cells into antibody secreting plasma cells 
(Kurosaki et al, 2010;Janeway CA, 2005). Mature circulating B-cells depend on the surface 
expression of BCR for survival also in the absence of antigen and it is thought that this is due to 
a “tonic” BCR-signaling. However, the exact mechanism for the “tonic” BCR-signaling is largely 
unknown. 
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Activation of T-cells 
As previously outlined, the CD4 positive T-cells comprise the T-helper cells, including the Th1-
cells, Th2-cells and the subset of follicular T-helper cells as well as the T-regulatory cells (Tregs). 
T helper-cells are activated by recognition of antigen-peptide bound to MHC II on antigen 
presenting cells (APCs). APCs are present in a large number in skin and mucosa and actively 
sample extracellular proteins by phagocytosis and endocytosis. APCs are activated by innate 
immune stimuli which induce MHC II expression and stimulate migration of APCs to a regional 
lymph node where the encounter with T-helper cells takes place (Bonilla and Oettgen 2009). 
Activated Th1-ĐĞůůƐ ƐĞĐƌĞƚĞ ĐǇƚŽŬŝŶĞƐ ƐƵĐŚ ĂƐ /E&ɶ ĂŶĚ dE&ɲ ǁŚŝĐŚ ŝŶ ƚƵƌŶ ƐƚŝŵƵůĂƚĞ
macrophages to kill intracellular pathogens by increased NO production. Activated Th2 cells 
secrete IL-4 and other cytokines which support B-cell proliferation and differentiation (Janeway 
CA, 2005). 
Figure 5. B-cell receptor signaling. Cross-linkage of two surface receptors by antigen activates a 
cascade of intracellular signaling that regulates the proliferation and differentiation of B-cells in 
the germinal center reaction. Detailed in the main text. 
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Cytotoxic T-cell expresses CD8 and their TCRs recognize foreign peptide bound to self 
MHC I of an infected cell. The binding of an activated cytotoxic T-cell to an antigen-MHC class I 
complex results in a directed release of cytotoxic granules. The granules contain perforin and 
granzymes which activates apoptosis in the infected target cell. In addition, engagement of Fas 
on target cell by Fas-ligand on the T-cell induces apoptosis of the infected cell (Janeway CA, 
2005).  
The T-cell response also results in immunological memory. There are two main subsets 
of memory T-cell derived both from CD4 and CD8 positive T-cells; TEM (effector memory) and 
TCM (central memory). TEM cells are located in the periphery; in the mucosa of the airway and 
gut and in the liver, while the TCM cells home to lymph nodes and tonsils (Kalia et al, 2006).  
Introduction to lymphomas 
Malignant lymphomas are tumors of immune cells in the lymphoid tissues, primarily the lymph 
nodes. The two main groups are Hodgkin’s lymphomas and non-Hodgkin’s lymphomas. The non-
Hodgkin’s lymphomas (NHLs) comprise a heterogeneous group of diseases caused by neoplastic 
proliferation of B- or T-lymphocytes. The wide spectrum of clinical presentations span from 
small localized lesions causing minimal symptoms to bulky lesions and disseminated tumor 
growth accompanied by threatened organ function and leading to severe reduction in the 
patient’s general condition. The WHO classification of 2008 subdivides the NHLs into a plethora 
of distinct entities based on the combination of clinical information, histological and 
morphological features of the tumor tissue, phenotyping of tumor cells by immunological 
methods as well as detection of genetic abnormalities in tumor cells (Swerdlow SH, 2008). The 
lymphoma types and subtypes require different treatments and patient outcome varies 
markedly. 
The two most common types of NHL are diffuse large B-cell lymphoma and follicular 
lymphoma, each of them accounting for about 30% of all new NHL cases in Europe and America. 
Both types are thought to arise from germinal center B lymphocytes in the lymph node. FL 
affects the middle-aged and elderly population and exhibits a variable clinical course with a 
median survival of at least 10 years. Initially, FL is often responsive to immunotherapy, 
chemotherapy and/or radiotherapy. However, the vast majority of patients experience relapses 
and progression to treatment resistant disease or transformation to higher-grade lymphoma 
with poor treatment outcome. Disease onset is more acute in DLBCL than in FL and DLBCL 
progress more rapidly. However, fifty to sixty percent of patients achieve durable remissions 
and there are few disease specific deaths beyond 5 years following treatment with immuno-
chemotherapy regimens containing antracyclines. Among the remainder of patients with 
incomplete treatment response or early relapse a proportion can be cured by high dose 
chemotherapy followed by autologous stem cell support to rescue bone marrow function. 
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The heterogeneous outcome observed both in FL and DLBCL has motivated the search 
for prognostic and predictive markers. The reliable identification of patients at low or high risk 
may then provide a rationale for differentiated treatment with an optimized balance between 
toxicity and benefit. Furthermore, a detailed knowledge about molecular mechanisms 
underlying different disease phenotypes may reveal targets for new treatment strategies. 
The advent of new methods for whole genome analyses during the two last decades has 
offered possibilities for large scale screening of tumor genomes in the search for genetic 
markers for prognosis. The extensive data produced from large scale genetic analyses have also 
generated hypotheses for disease mechanisms and identified potential treatment targets. 
Testing of such hypotheses in cancer cell lines and mouse models for cancer have provided new 
insight to tumor biology and resulted in development of new therapeutic agents for several 
cancer types. 
As the focus of this thesis is on FL, the following sections describe in some detail clinical 
features, histopathology and molecular pathology of FL. Descriptions of other lymphoma 
entities are included to create a broader context for certain aspects of FL. 
Classification of lymphomas 
The medical and scientific history of lymphomas demonstrates the power of systematic 
observation and classification in biological research. The discovery and characterization of 
lymphoma subgroups hand in hand with advances in molecular biology and genetics has led to 
development of more specific treatment strategies followed by significant improvement in 
survival of lymphoma patients. 
The history of lymphomas began in 1832 with Thomas Hodgkin’s publication “On Some 
Morbid Appearances of the Absorbant Glands and the Spleen” (Aisenberg, 2000). In this 
publication Thomas Hodgkin made the distinction between inflammatory processes and the 
condition that would later be recognized as Hodgkin’s disease (first by Wilks in 1865).  
Sternberg and Reed (in 1898 and 1902, respectively) defined the microscopic features of 
the neoplastic cells in Hodgkin’s disease, which later were designated Reed-Sternberg cells (RS-
cells). However, Hodgkin’s disease was not recognized as a lymphoid neoplasm and renamed 
Hodgkin’s lymphoma until the 1990s when the development of PCR (polymerase chain reaction) 
with primers for IgH gene loci and techniques for micro dissection of RS-cells proved that these 
were clonal B-cells (Jaffe et al, 2008).  
The first classification of lymphomas was proposed in 1966 by Rappaport in USA and 
mainly distinguished the nodular from the diffuse growth pattern of malignant cells (Rappaport, 
1966). A more comprehensive classification was developed in the Working Formulation which 
also stratified lymphomas based on the clinical outcome (low-grade, intermediate grade, and 
high-grade) (The Non-Hodgkin's Lymphoma Pathologic Classification Project, 1982). In contrast, 
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the Kiel classification of 1974 used in Europe, categorized lymphomas according to their 
hypothetical counterparts in the scheme of normal lymphocyte differentiation (Lennert, 
1978;Lennert, 1992). The different classification schemes and treatment traditions made it 
difficult to compare clinical studies from centers across the Atlantic. The REAL classification 
proposal of 1994 resulted from a series of meetings between European and American 
haematopathologists and represented a new paradigm in lymphoma management (Harris et al, 
1994). Based on published data and consensus among lymphoma experts distinct disease 
entities were defined from a constellation of features: morphology, immunophenotype, gentic 
abnormalities and clinical information. Some broad categories had to be made because of 
limitations in current knowledge (i.e DLBCL with a range of morphological variants) thereby 
pointing out fields in the need of further study. The WHO Classification of 2001 was a 
continuation of this work that also pointed out the necessity of differential treatment of 
separate lymphoma entities. A revision was published in 2008 which emphasized the need for 
predictors of prognosis in the common lymphomas, such as DLBCL, FL and peripheral T-cell 
lymphomas (Swerdlow SH, 2008;Jaffe et al, 2008). 
As opposed to carcinomas, malignant lymphomas can very rarely be cured by surgery. 
Shortly after the detection of x-ray and the radioactive radium isotope, radiation was tested as 
treatment for several cancer diseases, including HL (Easson & Russell, 1963).  Different 
schedules for radiotherapy in HL were developed during the first half of 1900, and by the 1960s 
extensive radiotherapy became the standard treatment for HL (Kaplan & Rosenberg, 
1966;Rosenberg et al, 1972). The development of chemotherapeutic agents started with the use 
of the mustard gas derivate nitrogen mustard during World War II. Its activity against HL and 
chronic leukemia was reported by Gilman and Philips and others in 1946 (GILMAN & PHILIPS, 
1946). The benefit of nitrogen mustard in HL stood out and fuelled the discovery, development 
and clinical testing of new agents and combinational chemotherapy regimens. As of today, a 
high proportion of HL patients are cured by either chemotherapy alone or in combination with 
limited radiotherapy and the focus is to reduce long term adverse effects of treatment while 
maintaining the excellent survival figures. 
NHL has lagged behind HL in classification and treatment results. The WHO 
classifications of 2001 and 2008 represent important milestones for the development of 
subtype specific treatment protocols (Swerdlow SH, 2008). Especially during the last two 
decades we have seen substantial improvements in outcome of NHL. This has been achieved by 
the combination of improved diagnostic precision, development of intensified chemotherapy 
regimens hand-in-hand with improved supportive case and during the last decade molecular 
targeted therapy. 
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Epidemiology of lymphomas 
Most epidemiological studies have focused on the non-Hodgkin’s lymphomas (NHL) as a whole 
and comprehensible epidemiological surveys of the individual subgroups have naturally lagged 
behind the refinement of lymphoma classification.  Ninety percent of lymphoid neoplasms 
occurring worldwide are mature B-cell neoplasms, and these are most common in the 
developed countries of Western Europe, USA, New Zealand and Australia. FL and DLBCL are the 
most common subtypes, accounting for 60 % of NHLs in these countries (Swerdlow SH, 2008). 
Generally, the incidence rate of NHLs is rising worldwide, more in Western developed countries 
than in Africa and Asia (Muller et al, 2005). In the USA the age-adjusted rates of NHL increased 
by 3-4% annually until the 1990s, when incidence rates stabilized, showing a 1-2% annually 
increase thereafter (Figure 5) (SEER, NCI, April 2010, accessed 04.09.2010). A similar trend has 
been observed in many European countries (Bosetti et al, 2008). In Norway, the NHL incidence 
rate has increased steadily by 2-3% annually since the 1970s (Figure 6) (The Norwegian Cancer 
Registry, 2008, date of data retrieval 27.08.2010). Increasing NHL-incidences has been observed 
in both sexes, the age groups above and below 65 and all ethnic groups living in Western 
Countries. NHLs in general, are more frequent among males than females and occur most 
frequently among elderly persons, with increases in age-specific incidence especially after the 
age of 55 (Muller et al, 2005;Morton et al, 2006).  
 
 
 
 
 
 
 
 
Figure 6. Incidence of non-Hodgkin’s lymphoma in the United States (left panel; US standard 
population) and Norway (right panel; world standard population). In the right panel, incidence 
rates are shown separately for men (blue marks) and women (red marks). 
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The Cancer Registry of Norway has collected national data about cancer incidence and 
prevalence since 1951. All physicians are instructed by law to notify the registry about new 
cancer cases. This combined with the unique personal identification number used in Norway 
secures a high degree of data completeness. Figure 7 and the table below are based on data 
from the Cancer Registry of Norway and show the national incidence and prevalence of FL, 
respectively (date of data retrieval 03.09.2013).  
 
   
  Number of years after primary diagnosis 
 Number of patients alive per 31.12.2011 <1 1-4 5-9 
Men 607 90 290 227 
Women 723 102 336 285 
Both sexes 1330 192 626 512 
 
 
Table 1. Prevalence of FL in Norway. 
 
 
Data scarcity in cancer registries of less developed countries in Asia and Africa limits the 
analysis of global distribution patterns of the major NHL subtypes. Nevertheless, some trends 
are notable. FL is relatively more common in the United States (US) than in Europe, accounting 
for уϯϬйĂŶĚуϮϬйŽĨE,>Ɛ͕ƌĞƐƉĞĐƚŝǀĞůǇ͕ǁŚŝůĞ ŝŶĨƌŝĐĂĂŶĚƐŝĂ&> ŝƐƌĂƌĞ͘ŶĚĞŵŝĐƵƌŬŝƚƚ͛Ɛ
lymphoma caused by Ebstein-Barr virus (EBV) and enhanced by malaria is the most common of 
NHLs in Africa. The overall frequencies of NHL is lower in Asia than in the US and Europe. On the 
other hand, primarily extranodal disease and peripheral T-cell NHL associated with EBV and 
human T-cell leukemia/lymphoma virus type 1 (HTLV-1) is relatively more frequent in Asians 
(Muller et al, 2005;Swerdlow SH, 2008). 
Increasing incidence rates can only partly be explained by factors such as improved 
cancer reporting, changed lymphoma classification, more sensitive diagnostic techniques and an 
increasing proportion of elderly people in the populations of Western Countries. The causes 
underlying a large proportion of additional NHL cases remain unknown. In the 1980s and 1990s, 
AIDS-associated lymphomas contributed to the increased NHL-incidence, particularly in young 
adult males, and a decreasing incidence in this group during the more recent years is due to the 
introduction of effective anti-retroviral therapy (HAART)(Fisher & Fisher, 2004;Morton et al, 
2006). In addition to HIV infection, other conditions causing immunosuppression have been 
linked to NHL risk. Immunosuppressive treatment for autoimmune diseases and following organ 
transplantation as well as congenital immunodeficiencies predispose patients for NHL (Fisher & 
Fisher, 2004;Muller et al, 2005). Autoimmune diseases such as rheumatoid arthritis, Sjøgren’s 
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disease and celiac disease are also associated with increased NHL-risk, independent of 
immunosuppressive treatment, indicating a role for persistent inflammatory activity in the 
etiology of NHL. Chronic inflammation caused by viral infections has also been linked to some 
types of NHL. Besides its role in endemic Burkitt’s lymphoma, EBV is present in NHLs associated 
with immunosuppression; in AIDS-patients and in organ-transplant recipients. Other well 
documented examples are the association of adult T-cell lymphoma with HTLV-1 infection in 
endemic areas of Asia as well as the association of Helicobacter pylori infection with gastric 
NHLs (Fisher & Fisher, 2004;Muller et al, 2005). Although exposure to environmental agents 
such as agricultural pesticide, hair dye and UV radiation has been linked to NHL-risk, it is unclear 
to what extent such factors contribute to the increase in NHL-incidence (Fisher & Fisher, 
2004;Muller et al, 2005).  
 
 
  
 
 
Figure 7. Incidence of follicular lymphoma in Norway 2002-2011. Data from the Norwegian 
Cancer Registry. Upper panel: Absolute numbers for both sexes (green), men (blue) and 
women (red). Lower panel: Age adjusted incidence rate, new cases per 100 000 person years, 
world  standard population (Doll 1966) 2002-2011 for both sexes (green), men (blue) and 
women (red).
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Generally, NHL mortality rates rose up to the mid-1990s. For the last decade declining 
morality rates have been observed in the countries of Western Europe and the US (Bosetti et al, 
2008). Also, improved survival from NHL has been reported from cancer registries and 
population-based studies in Western countries (Sehn et al, 2005;Luminari et al, 2007;Keegan et 
al, 2009) (Figure 2). This trend is mainly attributable to improved treatment outcome of mature 
B-cell lymphomas by the introduction of the monoclonal anti-CD20 antibody rituximab in 1997 
(Sehn et al, 2005;Molina, 2008;Keegan et al, 2009). A similar trend has not been observed for 
the peripheral T-cell lymphomas (Abouyabis et al, 2008). The use of high-dose therapy with 
autologous stem-cell support for patients with refractory and relapsing DLBCL may to a 
moderate extent also contribute to the improved outcome. Data from the lymphoma data base 
at our institution shows the improvement in outcome for patients with indolent non-Hodgkin’s 
lymphomas (Figure 8). 
 
 
 
  
Figure 8. Relative survival of patients with indolent non-Hodgkin’s lymphomas according to the 
year of primary diagnosis. Data from the lymphoma data base at Oslo University Hospital, the 
Norwegian Radium Hospital. 
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Histopathology of FL 
In 1925, Brill et al described patients with enlarged lymph nodes and spleen, pathologically 
characterized by proliferation of lymphoid follicles and he was the first to recognize FL as a 
distinct disease entity (Aisenberg, 2000; van & Schouten, 2007). Additional cases were reported 
during the following years also describing the progression to large-cell neoplasm (van & 
Schouten, 2007; Jaffe et al, 2008; Swerdlow SH, 2008).  
The malignant B-cells of FL are organized in a follicular growth pattern resembling the 
secondary follicle of a reactive germinal center, hence the name follicular lymphoma. The 
follicles are densely packed, often lacking mantle zones. Unlike the B-cells of a reactive germinal 
center, the centrocytes and centroblasts of FL are not polarized into light and dark zones, but 
reside and proliferate intermingled. FL cells are positive for B-cell associated antigens such as 
CD19, CD20, CD22 and CD79a as well as for germinal center B-cell markers such as CD10 and 
Bcl-6. CD5 and CD43 immunostaining is negative in FL, as opposed to chronic lymphatic 
leukemia. In contrast to B-cells of a normal germinal center, FL cells are positive for the anti-
apoptotic protein BCL2 in most cases (Figure 9). The aberrant expression of BCL2 is due to the 
presence of the chromosomal translocation t(14;18) which will be described in detail in the 
section “Molecular pathology of lymphomas”.  
 
 
 
 
Figure 9. Immunohistochemical staining of follicular lymphoma showing that the malignant B-
cells are positive for the B-cell marker CD20, the germinal center B-cell markers CD10 and Bcl-6. 
In addition, the malingnat B-cells of follicular lymphoma show aberrant expression of the anti-
apoptotic protein Bcl-2.
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There is a close relationship between FL-cells and the meshwork formed by the follicular 
dendritic cells as visualized by CD23 and CD21 immunostaining. In addition, the neoplastic 
follicles contain follicular T helper cells positive for CD4 and CD57. The interfollicular areas are 
composed of variable elements of T-cells, macrophages, micro vessels and fibroblasts (Figure 
10).  
 
 
 
 
 
 
 
 
 
 
 
 
FLs are graded from 1 to 3a or 3b according to the content of centroblasts as determined by 
counting of 10 high power fields (40xobjective and 18 mm field of view). FL grade 1-2 are 
grouped together in the latest revision of the WHO classification and is dominated by 
centrocytes, containing up to 15 centroblasts per high power field. FL grade 3 is subdivided into 
3a and 3b, the former containing >15 centroblasts/hpf and the latter showing solid sheets of 
centroblasts (Swerdlow SH, 2008). Although this method shows poor reproducibility, it has 
CD3 staining
Figure 10. Immunohistochemical staning with markers for cells present in the 
microenvironment of follicular lymphoma. Anti-CD21 is a marker for Follicular Dendritic cells 
and the staining shows how their elongated cytoplasmatic processes  form a network around 
the malignant B-cells. Anti-CD34 is a marker for endothelial cells and the staining shows how 
microvessels are mainly located tin the inter follicular area. Anti CD68 is a marker for 
macrophages that mostly reside in the interfollicular area with a few macrophages also 
present within the neoplastic follicle. CD3 is a pan T-cell marker and the staining shows  the 
location of T-cells both inter- and intrafollicularily.
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clinical relevance as the higher grades of FL, particularily FL grade 3b, shows a more aggressive 
clinical behavior. 
Upon higher-grade transformation the follicular growth pattern is lost and larger, blast-
like cells growing in diffuse areas take over, commonly showing the histological features of 
Diffuse Large B-Cell Lymphoma (DLBCL) (Figure 11), or more rarely a Burkitt-like lymphoma 
harboring chromosomal rearrangements of both BCL2 and MYC. Areas of FL may be retained 
adjacent to the diffuse areas in a composite lymphoma.  
  
Figure 11. Transformation from FL to DLBCL. Two sections of paraffin-embedded tumor tissue 
obtained from the same patient at the time of primary diagnosis (left) and at the time of 
transformation (right). Immunohistochemical staining with anti-CD20 antibodies shows the 
different distribution of malignant B-cells before and after transformation. The follicular 
growth pattern in the primary follicular lymphoma sample is lost in the sample showing DLBCL. 
In the primary sample the majority of tumor cells within a neoplastic follicle morphologically 
resemble centrocytes, while in the transformed sample shows large, blast-like cells. The 
magnification is the same in the two square shaped detail images, clearly showing the 
differences in cell size in FL and DLBCL.
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Clinical features and treatment of FL  
The Norwegian national treatment recommendations below are given according to the national 
guidelines, which are generally in line with the referenced international recommendations  
(http://helsedirektoratet.no/publikasjoner/nasjonalt-handlingsprogram-med-retningslinjer-for-
diagnostikk-behandling-og-oppfolging-av-maligne-lymfomer/Sider/default.aspx).  
Patients most commonly present with moderately enlarged peripheral lymph nodes. The 
clinical symptoms and signs often develop gradually; lymph node enlargement may have been 
modest or occult for a long time before clinical recognition, and FL is commonly disseminated at 
the time of diagnosis. Symptoms may also arise from enlargement of deep nodes, mostly 
infradiaphragmatic, which threaten normal organ function causing hydronephrosis, intestinal 
obstruction, compression of vena cava inferior or cholestatsis. Primary mediastinal or spleen 
involvement is rare. The patient’s general status is commonly preserved and a minority of 
patients has B-symptoms (night sweats, persisting fever and unexplained weight loss).  Bone 
marrow involvement is found in 50-60% of cases at diagnosis. Less common presentation forms 
are extranodal FL, FL limited to the gastro-intestinal tract or to skin, FL in situ and pediatric FL.  
Follicular lymphoma is staged according to the modified Ann Arbor classification (see for 
instance (Gospodarowicz, 2009)) based on results from the clinical examination, a CT-scan 
including neck, thorax, abdomen and pelvis, blood sampling and a bone marrow biopsy. PET-CT 
has limited additional value, as most cases are classified as disseminated disease by 
conventional staging methods, but may be useful to confirm localized disease prior to planning 
of curative radiotherapy. 
The Follicular Lymphoma Prognostic Index (FLIPI) is made up of the following five clinical 
criteria (Solal-Celigny et al, 2004); age шϲϬǇĞĂƌƐ͕ŶŶƌďŽƌƐƚĂŐĞ/// -IV, hemoglobin level < 12 
g/L, involved lymph node regions > 4 and serum LDH шƵƉƉĞƌƌĞĨĞƌĞŶĐĞǀĂůƵĞ͘ǇƚŚĞ se criteria, 
patients can be allocated to low (0-1 criterion), intermediate (2 criteria) and high risk (3-5 
criteria) groups with significantly different survival. Each risk group comprises roughly one third 
of the patients at primary diagnosis. FLIPI and other clinical factors with prognostic value 
probably reflect different biological features of the disease (and its interaction with the host) 
already at primary diagnosis. However, patients with limited extent of disease combined with 
aggressive features and patients with advanced extent disease and indolent course may be 
misclassified in low and high risk groups, respectively. The FLIPI-score is considered for 
stratification of treatment for individual patients, but its poor specificity and sensitivity in 
predicting the disease course has limited its use in clinical studies and in translational research.  
The choice of treatment strategy is based on an individual evaluation taking into account 
the patient’s age, general health and degree of affliction. The FLIPI score is used to assess 
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disease extent and aggressiveness. No studies have shown any survival benefit from early 
treatment initiation in asymptomatic patients and no studies have shown survival benefit from 
early administration of intensified treatment regimens (Ghielmini et al, 2013).  Patients with a 
low FLIPI-score who are in a good condition with diminutive symptoms can be observed 
untreated (“watch and wait”). Eventually, disease progression with declining general condition, 
uncomfortable lymph node enlargement, signs of bone marrow failure, B-symptoms or organ 
complications necessitate treatment. In younger patients and patients presenting with bulky 
tumor or intermediate to high FLIPI-score at diagnosis treatment is usually initiated early. Less 
than one third of patients have limited disease (stage I-II) at disease presentation. If involved 
lymph nodes can be included in one small to medium sized radiation field, radiotherapy (2Gy x 
12) with curative intention is the treatment of choice. Nevertheless, half of these patients 
experience relapse and subsequently receive chemo-immunotherapy. 
The standard first line therapy for most patients consists of a combination of 
immunotherapy with the anti-CD20 antibody rituximab and chemotherapy: bendamustine or a 
combination of cyclophosphamide, vincristine and prednisolone with or without doxorubicine 
(commonly abbreviated CHOP or COP, respectively). Rituximab monotherapy in first line is also 
widely used today, especially in cases where it is desirable to postpone chemotherapy. 
Maintenance rituximab treatment has been shown to confer improved progression free 
survival. Chlorambucile, which also may be combined with immunotherapy, is an alternative for 
elderly patients, but may be detrimental for the bone marrow function and increase the risk for 
secondary myeloid neoplasia and for inadequate bone marrow harvest yield for patients eligible 
for autologous bone marrow transplantation at a later stage. Treatment response is usually very 
good and in the majority of patients a CR or a good PR is achieved after 6 courses (4 months of 
treatment). At relapse of follicular lymphoma, different treatment options can be chosen based 
on an individual evaluation. If a good and long-lasting response to rituximab (R), R-
Bendamustine or R-COP was obtained in first line, the same or the alternative regimen may be 
chosen. Maintenance rituximab immunotherapy is recommended if not given up front. In the 
case of more aggressive disease various chemotherapeutic agents have documented effect in 
FL; bendamustine, COP, CHOP and fludarabine, all in combination with rituximab are commonly 
used also at relapse. Trofosfamid is an alternative for patients with reduced tolerance for the 
toxic effects of combinatorial regimens. For patients relapsing after a shorter period or who do 
not respond, high dose therapy with autologous stem cell support (HD-ASCT) may be the 
treatment of choice (Ghielmini et al, 2013;Montoto et al, 2013).  
The median overall survival in FL was reported to be 7-12 years in the pre-rituximab era. 
The classical survival curve in FL drops in an almost linear fashion demonstrating the 
heterogeneous course and lethal outcome of the disease. Common causes of death are 
treatment resistant FL, higher-grade transformation or inability to tolerate further treatment.  
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The advent of rituximab in the late 1990’ies, a monoclonal humanized antibody directed 
against the B-cell marker CD20 has revolutionized the treatment of B-cell lymphomas (see for 
instance (Sehn et al, 2005)). In Norway, rituximab became part of the routine treatment of 
follicular lymphoma and DLBCL in the beginning of the second millennium. The use of rituximab 
together with improvements in diagnostics of FL and the treatment of transformed FL have 
resulted in improved survival. However, recent data still indicate that FL relapses and remains 
incurable (Salles, 2007;Conconi et al, 2012). 
Definition and treatment of transformed lymphoma 
Transformation to an aggressive and often treatment resistant phenotype occurs in various 
proportions of patients in several of the mature B-cell neoplasms and is associated with short 
survival. In FL, transformation has been reported to occur in 10-70% of patients, depending on 
the diagnostic method (histological examination, clinical criteria or detected at autopsy), the 
observation time and the frequency of biopsies taken during the course of disease (Acker et al, 
1983;Garvin et al, 1983;Horning & Rosenberg, 1984;Bastion et al, 1997;Gine et al, 
2006;Montoto et al, 2007;Al-Tourah et al, 2008;Conconi et al, 2012). The probability of 
transformation seems to be constant at least during the first 5-10 years of observation, and 
after 10 years of observation approximately 30 % of patients have experienced transformation, 
resulting from a transformation rate of approximately 3 % per year. Whether or not the 
transformation rate declines in patients remaining at risk thereafter has not been clear and the 
existing data are conflicting (Montoto et al., 2007; Al-Tourah et al., 2008). Neither the timing of 
treatment onset (immediately following diagnosis of FL versus “watch and wait”), nor the 
intensity of the primary treatment regimen influenced the incidence of transformation 
according to most previous studies (Acker et al 1983, S Horning et al 1984, Yuen et al 1995, Al-
Tourah et al., 2008; Conconi et al., 2012). Then again, a recent study reported significantly lower 
transformation rate in patients who received rituximab in monotherapy as first line treatment 
compared to patients that had been observed untreated initially. This indicates a reduced 
transformation rate of FL in the rituximab era (Link et al, 2013). 
Before the WHO 2008 classification discriminated between FL grade 3a and – grade 3b, 
grade 3 was considered more aggressive than grade 1 and 2, and was treated like DLBCL at 
many centers. Thus, follicular lymphomas with increasing grade from 1 and 2 to grade 3 were by 
many clinicians considered as a transformation. In the beginning of the millennium data 
supporting a subdivision between FL grade 3a and 3b was published (Ott et al, 2002), and more 
recent studies have confirmed that FL grade 3b represents a separate entity with different 
molecular features (Piccaluga et al, 2008;Horn et al, 2011) accounting for у ϱ й ŽĨ &>Ɛ͘ The 
clinical significance of distinguishing between FL grade 3a and 3b has been a matter of debate as 
studies assessing survival (OS and PFS) according to FL grade have shown conflicting results 
41 
 
(Shustik et al, 2011). A recent population based study with long term follow-up data confirmed 
the aggressive clinical course of FL grade 3b (Wahlin et al, 2012). About 50% of patients FL grade 
3b relapsed and died within 5 years, whereas уϳϱйŽĨƉĂƚŝĞŶƚƐǁŝƚŚŐƌĂĚĞϭ-3a were still alive 5 
years after diagnosis. Thereafter the OS curve for FL 3b showed a plateau, indicating that a 
proportion of these patients were cured, while the OS curve for FL grade 1-3a showed a steady 
decline. The prognostic significance of FL grading seems to depend on treatment, as the OS was 
better for the patients with FL grade 3a than FL grade 1-2 when treated with rituximab 
monotherapy in first line (Wahlin et al, 2012;Wahlin et al, 2013). Based on the study by Ott et al 
(Ott et al, 2002) and other publications during the first decade of 2000 the definition of 
transformation was limited to the progression from FL of any grade to DLBCL. Then again, the 
prognostic significance of progression from FL grade 1-2 to grade 3a or b at relapse has been 
poorly studied.  
Obtaining a representative biopsy is sometimes difficult as the site of transformation 
may be challenging to access surgically. The appearance of a least one of the following clinical 
characteristics  in a patient with a history of FL, is associated with the same outcome as for 
patients with histologically verified transformation; rapid, discordant tumor growth, 
involvement of unusual extranodal site, new B symptoms, hypercalcemia or sudden rise in LDH-
level (Al-Tourah et al, 2008). The diagnosis of transformed lymphoma should in such cases be 
based on these clinical findings and treatment planned accordingly. 
In a large Canadian population based study of more than 300 cases of FL with 
observation times exceeding 15 years (median 109 months) (Al-Tourah et al, 2008) the 10 year 
survival rates were 36% and 75% for the patients with and without transformation, respectively. 
In the same retrospective analysis median survival following transformation was only 1.7 years. 
Traditionally, patients with transformed non-Hodgkin’s lymphoma (t-NHL) have received salvage 
treatment with combination chemotherapy regimens like CHOP, alternatively dexamethasone, 
cytarabine and cisplatin (DHAP), ifosfamide, carboplatin and etoposide (ICE) or etoposide, 
ifosfamide and methotrexate (VIM) in cases where doxorubicin has to be avoided (elderly, 
patients with heart disease or patients that already received doxorubicin-containing regimens 
for their FL). Despite remission rates (CR) of up to 40%, the median overall survival obtained 
with these treatment lines was only in the range of 7 months to 1.7 years (Yuen et al, 
1995;Bastion et al, 1997;Gine et al, 2006;Montoto et al, 2007;Al-Tourah et al, 2008). Then again, 
a subgroup of patients in CR after salvage treatment obtained long-term survival (Yuen et al, 
1995). Studies prior to 1999 (the opening year of the study presented in Paper 2) had shown 
longer survival in patients with localized transformation, no previous chemotherapy, no B 
symptoms, a normal LDH-level as well as in patients attaining CR after salvage chemotherapy 
(Yuen et al, 1995;Bastion et al, 1997). On the other hand, it was known that post-transformation 
survival did not dependent on the interval from primary diagnosis to transformation (Yuen et al, 
1995).  
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In a tumor biological perspective; the extent of disease, increased levels of LDH and 
beta2-microglobulin can be considered as markers for the proliferation rate of the tumor, while 
the attainment of partial remission (PR) or CR is a marker for chemo-sensitivity. Thus, bringing 
more patients into CR following transformation may improve the long-term outcome. High-dose 
chemotherapy with autologous stem cell support (HD-ASCT) is the standard treatment for 
recurrent and primarily treatment resistant DLBCL. This was established following the Parma-
study (Philip et al, 1995) in which 215 patients with relapsed intermediate grade (n=163) and 
high grade (n=52) non-Hodgkin’s lymphoma were first treated by two courses of conventional 
chemotherapy (DHAP=dexamethasone, cytarabine, cisplatin). The patients who responded 
(n=109) were randomized to treatment with high-dose chemotherapy followed by autologous 
bone marrow transplantation (n=55) or to continue conventional chemotherapy treatment 
(n=54). The rates of event-free survival and overall survival were significantly higher in patients 
receiving HD-ASCT. This formed a rationale for testing of HD-ASCT in various disease stages of FL 
(Al et al, 2012;Schaaf et al, 2012), and particularly in transformed FL. Retrospective studies of 
limited size (Foran et al, 1998;Friedberg et al, 1999;Chen et al, 2001;Williams et al, 
2001;Andreadis et al, 2005;Sabloff et al, 2007;Hamadani et al, 2008) indicated a beneficial 
effect of HD-ASCT in transformed FL, as will be discussed below.  
In HD-ASCT chemotherapy and / or total body radiation (TBI) is administrated in doses 
exceeding the tolerance of the hematopoietic stem cells with the aim to completely eradicate 
the neoplastic lymphoid cells. In advance, the patient’s own hematopoietic stem cells are 
mobilized harvested from peripheral blood. The autologous stem cells are re-infused 
intravenously following HD-ASCT and re-populate the bone marrow  restoring hematopoiesis. 
Only patients with disease response to immuno-chemotherapy will benefit from HD-ASCT. 
Patients achieving at least a PR following 2-3 courses of an induction regimen are eligible. 
Hematopoietic CD34+ stem cells are efficiently mobilized from the bone marrow to 
peripheral blood by combining chemotherapy and G-CSF. From the majority (90%) of patients 
the required amount of CD34+ cells (> 2.0 x 106 CD34+ cells/kg), is collected by one or more 
days of aphaeresis. A high number (> 5 x 106 CD34+ cells/kg) of re-infused stem cells is 
associated with faster hematological recovery, less bleeding- and infections complications and 
improved outcome following HD-ASCT.   
Even following HD-ASCT follicular lymphoma and transformed lymphoma show a 
notorious tendency to relapse. For relapses of the transformed component the prognosis is 
grave and there are no established treatment options. For relapses of the indolent component 
radio-immunotherapy can induce long-lasting remissions (Witzig et al, 2002b;Witzig et al, 
2002a;Vose et al, 2000;Kaminski et al, 2001;Illidge & Morschhauser, 2011). Allogeneic stem cell 
transplantation with reduced intensity conditioning (RIC-allo) has given long-term remissions in 
younger, selected patients (Mortensen et al, 2012;Khouri, 2011).  
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Molecular pathology of lymphomas 
The lymphoid neoplasms (leukemias and lymphomas) are tumors originating from clonal 
proliferation of B-cells and T/NK-cells at various stages of development and differentiation. The 
malignant lymphocytes often recapture features of their normal counterpart, an observation 
that has led to the “frozen stage hypothesis” of lymphoma development (Figure 11). . 
The initial step in lymphomagenesis is often chromosomal translocations occurring at 
different stages of lymphocyte development, leading to oncogene activation. This is supported 
by the observations that recurrent translocations are the most frequently  genomic aberrations 
in many lymphoma subtypes and some cases of lymphoma carry a translocation as the only 
detected genomic aberration. The first recurrent translocations to be recognized were the 
t(14;18) in FL and t(8;14) in Burkitt’s lymphoma. Specific translocations are closely associated 
with the different lymphoma entities (Table 2, next page).  
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Lymphoma entity Translocation Frequency Genes Oncogenetic mechanism 
B-lymphoblastic 
leukemia/lymphoma 
t(9;22)(q34;q11.2)   ABL and BCR Fusion protein; 
constitutively activated 
tyrosin kinase 
rearrangement of 11q23 6% MLL Various fusion proteins; 
disruption of MLL complex 
and inappropriate 
expression of HOX genes 
t(12;21)(p13;q22) 20-50%  TEL and AML 
(ETV6/RNX1) 
Fusion protein; function 
largely unknown 
t(5;14)(q31;q32)  IL3 and IGH Over-expression of IL3 
t(1;19)(q23;p13.3)  PBX and 
E2A(TCF3) 
Fusion protein; leading to 
inappropriate expression of 
HOX genes 
Burkitt’s lymphoma t(8;14)(q24;q32) 
or variants with 
translocation to light chain 
loci (2p12 or 22q11) 
100% C-MYC and IGH Over expression of the 
transcription factor Myc 
leading to increased 
proliferation 
DLBCL Rearrangement of 3q27, 30% BCL6 Over expression of the 
transcriptional repressor 
Bcl-6  
t(14;18)(q32;q21), 20-30% IGH and BCL2 Over expression of the anti-
apoptotic protein Bcl-2 
rearrangement of 8q24 
 
10% C-MYC 
 
Over expression of the 
transcription factor Myc 
leading to increased 
proliferation 
Follicular lymphoma t(14;18)(q32;q21)  
or variants with 
translocation to light chain 
loci (2p12 or 22q11) 
90% IGH and BCL2 Over expression of the anti-
apoptotic protein Bcl-2  
Mantel cell 
lymphoma 
t(11;14)(q13;q32)  
or variants with 
translocation to light chain 
loci (2p12 or 22q11 
95% CCND1 and IGH Over expression of the cell 
cycle regulator cyclin D1 
Extra nodal Marginal 
zone lymphoma 
(MALT) 
t(11;18)(q21;q21)  pulm/gast API2 and 
MALT1 
Fusion protein with MALT1 
activity leading to 
constitutive activation of 
the NF-ʃƉĂƚŚǁĂǇ 
t(1;14)(p22;q32)  BCL10 and IGH Over expression of Bcl-10, 
involved in activation of the 
NF-ʃƉĂƚŚǁĂǇ 
t(14;18)(q32,q21) oc ad/orb IGH and MALT1 Over expression of MALT1 
which activates the NF-ʃ
pathway 
t(3;14)(p14;q32) thyr/skin/oc 
ad/orb 
FOXP1 and IGH Over expression of the 
transcription factor FOXP1 
Anaplastic large cell 
lymphoma 
t(2;5)(p23;q35) 
and other rearrangements 
of 2p32 
90% ALK and NPM Fusion protein; 
constitutively active ALK, a 
receptor tyrosin kinase 
Table 2. Lymphoma entities and associated translocations. 
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Primary oncogenetic aberrations  
The physiological DNA modifications taking place during B-cell development and activation put 
B-cells at risk for genomic aberrations and point mutations. The recombination of V(D)J 
segments at the pro-B and pre-B stages of development, the somatic hypermutation (SHM) and 
class-switch recombination (CSR) occurring in germinal center B-cells all involve DNA double 
strand breaks (DSBs). These physiological breaks can persist over several cell divisions and 
erroneous repairing of the DSBs may lead to formation of chromosomal translocations. Indeed, 
the majority of recurrent translocations in lymphomas involve one physiologic DSB of an 
immunoglobulin loci and one pathologic DSB of a proto-oncogenes (Tsai & Lieber, 2010). The 
proto-oncogene thus comes under control of the active immunoglobulin promoter, resulting in 
oncogene activation by over-expression.  
The translocation t(14;18) characterizes 80-90% of follicular lymphomas and a 
proportion of diffuse large B-cell lymphomas. Yunis et al (Yunis et al, 1982) were the first to 
report of an association between FL and the t(14;18). A few years later the breakpoints on 
chromosome 14 and 18 were cloned (Tsujimoto et al, 1984). The physiologic break at IgVH-locus 
is mediated by RAG1/RAG2 and may occur during VDJ rearrangement in pro-B stage of 
development. Two studies (Raghavan et al, 2004;Raghavan et al, 2005) showed involvement of 
RAG1/RAG2 also in the breakpoint formation at the BCL2-locus. A specific DNA structure in the 
major breakpoint cluster of BCL2 was shown to be the basis for fragility. More recently it has 
been shown that the pathologic break occurs in three breakpoint clusters that are CpG sites 
within or proximal to the BCL2-gene. This indicates that off-site involvement of both AID and 
RAG1/RAG2 may cause DSB in the BCL2-locus (Tsai & Lieber, 2010).   
During the 1980’ies it was shown that the t(14;18) leads to expression of a BCL2-
immunoglobulin chimeric RNA in resting B-cells (Nunez et al, 1989). A few years earlier, the 
BCL2 protein and its expression in non-Hodgkins B-cell lymphomas bearing the t(14;18) had 
been described (Tsujimoto & Croce, 1986;Ngan et al, 1988) and finally the anti-apoptotic 
function of BCL2 was described by Hockenbery D et al (Hockenbery et al, 1990). As a 
consequence of the translocation, the BCL2 locus on chromosome 18 comes under control of 
the IgH promoter on chromosome 14, resulting in over-expression of the anti-apoptotic protein 
BCL2. As opposed to normal germinal center B-cells which are prone to apoptosis due to 
suppression of BCL2, the clonal B-cells carrying BCL2 escape apoptosis in the germinal center 
independently of antigenic specificity and survive to circulate for a long time. In FL cells there is 
ongoing SHM of the variable region of immunoglobuline heavy chain gene (IGVH), and this 
indicates that FL originates from the germinal center B-cells (Bahler et al, 1991;Hardianti et al, 
2004;Klein & la-Favera, 2008).  
Some cases of FL harbor the translocations t(2;18) and t(18;22) in which the BCL2 genes 
is juxtaposed to the kappa or lamda lighr chain locus respectively. These variants are also 
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associated with BCL2 over-expression. About 10% of FLs are negative for translocations 
involving BCL2. These are morphologically indistinguishable from the t(14;18)positive cases. 
Most of translocation negative cases are BCL2 negative at the protein level, although some 
cases may be negative due to mutated BCL2 and crippled antibody epitope. Some t(14;18)-
negative cases show up-regulation of alternative anti-apoptotic proteins such as Mcl-1 or Bcl-X. 
Translocations involving BCL6 at 3q27 are more common in t(14;18)-negative cases, resulting in 
over-expression of the BCL6 oncogene. The t(14;18)-negative cases commonly show higher 
levels of Ki67 and lower CD10-expression. They have the phenotype of late germinal center B-
cells, showing protein expression of IRF4/MUM1, a marker for activated B-cells and plasma cell 
differentiation (Leich et al, 2009). FL grade 3b more commonly harbors a BCL6 rearrangement 
and lacks the t(14;18), and is today considered a biologically distinct subtype of FL sharing many 
features with de novo DLBCL (Horn et al, 2011). 
DLBCL corresponds to germinal center B-cells and B-cells that are about to start plasma 
cell differentiation (also termed activated B-cells). A proportion of diffuse large B-cell lymphoma 
harbors translocations involving 3q27, the locus for BCL6. Translocations partners are various, 
frequently involving the Ig loci or other genes that are constitutively expressed in B-cells. The 
mechanism by which BCL6 promotes lymphomagenesis is not fully understood. It is thought that 
over-expression of BCL6 convey insensitivity to DNA damage and thus support genomic 
instability. In addition, high levels of BCL6 may block the differentiation to plasma cells (Basso & 
la-Favera, 2012).  
Burkitt’s lymphoma shares features with germinal center B-cells; they are positive for 
BCL6 and have mutated IGV genes. The hallmark translocation of Burkitt’s lymphoma, the 
t(8;14), is induced by AID and brings the MYC-oncogene on chromosome 8 under control of the 
Ig heavy chain locus on chromosome 14. Alternatively, the MYC-oncogene is brought under 
control of the Ig light chains on chromosome 2 or 22. The resulting over-expression of the MYC-
protein drives proliferation of the clonal B-lymphocytes (Molyneux et al, 2012).  
Marginal zone lymphomas of mucosa associated lymphoid tissue (MALT), splenic and 
nodal type resemble the memory B-cells derived from and homing to extranodal, splenic or 
nodal tissues. MALT lymphomas are associated with the translocation t(11;18) resulting in the 
fusion gene API2/MALT1. The protein product of this fusion gene has been shown to mediate 
constitutive activation of the non-canonical NF-kB pathway (Rosebeck et al, 2011). 
Mantle cell lymphoma corresponds to CD5+ naïve B-cells. The t(11;14) is present in large 
proportion of MCLs and results in over expression of the protein cyclin D1 which is a central 
regulator of cell cycle progression from G2- to M-phase. Variant translocations involving the 
same oncogene in combination with either one of the light chain loci on chr 2 and 22 for kappa 
and lambda, respectively, are also seen (Swerdlow SH, 2008).  
Plasma cell myeloma corresponds to the bone marrow homing plasma cell. About 40% 
of multiple myelomas (myelomatosis) harbor translocations involving the immunoglobuling 
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heavy chain locus at 14q32 and a heterogeneous set of oncogenes as translocation partners. A 
large proportion of tumors ( уϴϬйͿĂƌĞĚĞƉĞŶĚĞŶƚŽŶE&ʃƐŝŐŶĂůŝŶŐĨŽƌƐƵƌǀŝǀĂů (Swerdlow SH, 
2008). 
 
Figure 12. The dark and light orange circles represent the dark and light zones of a germinal 
center. The cell of origin for each of the B-cell lymphoma subtypes is illustrated and the 
hallmark genetic lesions contributing to malignant transformation is marked for each subtype.
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For some lymphoma entities the “frozen stage hypothesis” cannot be so easily applied. For CLL 
the cell of origin is poorly defined. Tumor cells in CLL express CD5 and CD23 and two main 
molecular subgroups have been identified; 50 % bearing mutated and 50% bearing un-mutated 
Ig variable regions. Mantle zone B-cells, marginal zone B-cells and the human equivalent of B-1 
cells have been proposed as the cell of origin. Neither does the neoplastic B-cell of hairy cell 
leukemia seem to have a normal counterpart. More recently, we have become aware of lineage 
heterogeneity and lineage plasticity; i.e. observations of FL transformation to histiocytic 
neoplasms and development of clonally related histocytic neoplasms from lymphoblastic B-cell 
and T-cell neoplasms challenge the “frozen stage hypothesis” (Jaffe et al, 2008). Furthermore, 
some lymphomas have characteristics of more than one type such as “B-cell lymphoma, 
unclassifiable, with features intermediate between DLBCL and classical HL”, often referred to as 
“Grey zone lymphoma”, and   “B-cell lymphoma unclassifiable, with features intermediate 
between DLBCL and Burkitt lymphoma”. The latter is also referred to as “double-hit 
lymphomas” as they harbor translocations of both BCL2 and MYC (Aukema et al, 2011). 
The T-cell neoplasms corresponds to innate and adoptive immunity T-cells. NK-cell lymphomas 
ĂŶĚɶɷd-cell lymphomas, arise predominantly in extra-nodal sites. T-cell lymphomas originating 
ĨƌŽŵɲɴd-cells are mainly of nodal origin. Generally, specific genetic abnormalities associated 
with T-cell lymphomas are not as well characterized as for the B-cell lymphomas. Most cases of 
anaplastic large cell lymphomas harbor the translocation t(2;5) or variants and express ALK, 
while hepatosplenic T-cell lymphoma is associated with an iso-chromosome of  arm 7q 
(Swerdlow SH, 2008). 
Secondary oncogenetic aberrations 
Although the characteristic chromosomal translocations may provide targeted B-cells with 
growth advantages, they are rarely sufficient to cause clonal expansion and lymphomagenesis. 
Mice bearing the BCL2 translocation develop hyperplasia of polyclonal mature B-cells, but fail to 
develop lymphoma (McDonnell et al, 1989). Furthermore, small populations of circulating 
t(14;18) positive lymphocytes are frequently found in the healthy adult and elderly population 
(Limpens et al, 1991), at a much higher incidence than that of FL (Dolken et al, 1996;Rabkin et 
al, 2008) indicating that the translocation itself is not sufficient for lymphomagenesis. 
Lymphomas commonly harbor secondary genomic aberrations, and recurrent chromosomal 
gains and losses have been associated with different lymphoma entities, with different 
phenotypes within entities and with treatment outcome. For instance, Burkitt’s lymphoma 
commonly exhibits a simple karyotype and loss of chromosome arm 13q is associated with 
inferior overall survival (Molyneux et al, 2012). In contrast, DLBCL and FL often have more 
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complex karyotypes with several chromosomal gains and losses, reflecting a higher degree of 
genomic instability.  
The mapping of secondary genomic aberrations in FL started in the 1970’ies. Using 
conventional karyotyping techniques, Yunis et al and others discovered that most FLs are 
hyperdiploid and profound aneuploidy is rare (Yunis et al, 1987). Several of the chromosomal 
gains and losses were recurrently observed in karyotypes from different tumors. Structural 
rearrangements in addition to t(14;18) also occur in FL, although these are more 
heterogeneous. The pattern of recurrent imbalances has later been confirmed and refined in 
several studies using techniques with higher genomic resolution. The most frequently observed 
aberrations occur in 10-50% of cases and comprise gains located on 1q, 2p, 6p, 7, 12/12q, 18, 22 
and X, while recurrent deletions are located on 1p36, 6q, 9p, 10q and 13q (see for instance 
(Yunis et al, 1987;Horsman et al, 2001;Bouska et al, 2013). Some of the recurrent chromosomal 
gains and losses have been associated with patient survival in FL (see for instance (Tilly et al, 
1994;Viardot et al, 2002;Cheung et al, 2008;Johnson et al, 2008). The aberrations commonly 
involve large chromosomal segments comprising hundreds or thousands of genes. Thus, target 
genes and potential drivers of lymphomagenesis in FL have been difficult to identify.  
New techniques (SNP arrays) enabled whole genome screening for loss of heterozygosity 
(also called acquired uniparental disomy; aUPD) in which one of the parental alleles is lost while 
the other is duplicated resulting in a balanced genomic aberration. In FL, aUPD recurrently 
targets chromosomal arms 6p, 16p, 12q, 1p36, 10q and 6q, and some of these have been 
associated with survival and transformation (Fitzgibbon et al, 2007;O'Shea et al, 2009;Bouska et 
al, 2013). 
In lymphomas oncogenic mutations may arise from aberrant SHM targeting genes other 
than the variable regions of heavy and light chain Ig genes. In a proportion of DLBCLs the 
pattern of accumulated mutations in the BCL6 gene reveals that the enzyme AID is involved. The 
aberrant SHM leads to increased expression of the transcription repressor BCL6 which promote 
lymphomagenesis (Basso & la-Favera, 2012). It has been shown that AID also targets other 
oncogenes such as MYC, RHOH, PIM1, PAX5, IRF4, BCL7A and BCL2 in DLBCL and other germinal 
center derived B-cell lymphomas, including FL. Aberrant SHM also contributes to inactivation of 
tumor-suppressor genes such as CD95 and SOCS1 in FL and other B-cell lymphomas (Pasqualucci 
et al, 2008;Mottok et al, 2009;Jiang et al, 2012). 
Expression of the B-cell receptor (BCR) is a consistent feature of B-cell lymphomas and 
the last decade of research has produced evidence for a role for BCR-signaling in 
lymphomagenesis. The mechanisms underlying aberrant BCR-signaling in lymphomas vary 
(Rickert, 2013). Cases of localized gastric marginal zone lymphoma which are associated with 
H.pylori infection can be cured by antibiotic eradication of the pathogen, indicating that antigen 
engagement of the BCR may fuel lymphoma development (Bayerdorffer et al, 1995). For CLL 
there is indirect evidence for stimulation of BCR by an antigen as one third of CLL cases express 
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stereotypic BCRs that are reactive to self-antigens (Murray et al, 2008;Rickert, 2013). BCR-
signaling is also involved in the pathogenesis of subsets of DLBCL (Lenz & Staudt, 2010). The role 
of BCR-signaling in FL poorly understood. This will be discussed below (“Gene dosage effect and 
potential cancer driver genes in FL”). 
Results from genome wide gene expression studies support and expand the cell of origin 
model in non-Hodgkin’s lymphomas (Alizadeh et al, 2000;Shipp et al, 2002;Lossos et al, 2004). 
The lymphoma entities can be distinguished by different gene expression profiles resembling 
the profiles of normal B-cells at different stages of differentiation (Shaffer et al, 2001;Shaffer et 
al, 2006). For instance, FLs show rather homogeneous genome wide expression profiles 
resembling the profile of germinal center B-cells, while DLBCLs are more heterogeneous and fall 
into three molecularly distinct subgroups which are undistinguishable in the microscope; the 
germinal center B-cell like (GCB) subtype, the activated B-cell (ABC) subtype and the primary 
mediastinal large B-cell lymphoma (PMLBCL) (Alizadeh et al, 2000;Wright et al, 2003). These 
molecular subgroups are associated with distinct clinical characteristics and different response 
to treatment. Whereas the majority of patients with GCB-DLBCL can be cured by R-CHOP-like 
regimens, 50% of patients with the ABC subtype die of lymphoma (Lenz et al, 2008b). The 
transcriptional program of GCB-DLBCL resembles B-cells at the stage of the germinal center 
reaction. For instance, there is ongoing SHM and usually expression of switched 
immunoglobulin classes (most commonly IgG). The GCB-DLBCLs are associated with over-
expression of BCL6 and translocations or mutations of the BCL6 gene are frequent (Lenz & 
Staudt, 2010). The gene expression profile of ABC-DLBCL have similarities with B-cells that are 
about to leave the germinal center and differentiate into plasma cells. ABC-DLBCLs express 
plasma cell differentiation markers like XBP1. However, inactivation of PRDM1 by different 
mechanisms blocks the terminal differentiation into plasma cells (Lenz & Staudt, 2010). The 
NFNB pathway is constitutively active, and inhibition of the pathway induces apoptosis in ABC-
DLBCL derived cell lines (Davis et al, 2001). The mechanisms for constitutive NF-kB activation 
involve activating mutations in mediators of BCR-signaling and TLR-signaling (Lenz et al, 
2008a;Davis et al, 2010;Ngo et al, 2011). The GCB- and ABC-subtypes of DLBCL also show 
different frequencies of primary and secondary chromosomal aberrations. The t(14;18), gain of 
2p15-16 and 12 are more frequent in GCB-DLBCL, while ABC-DLBCL have frequent gains of 3, 
18q and loss of 6q (Bea et al, 2005;Tagawa et al, 2005;Chen et al, 2006;Lenz et al, 2008c). 
Primary mediastinal large B-cell lymphomas (PMLBCL) have frequent gain of chromosome 9 and 
share similarities with Hodgkin’s lymphoma nodular sclerosis both in terms of molecular 
features and clinical characteristics (Alizadeh et al, 2000;Rosenwald et al, 2003).  
Although the genome wide gene expression profile of FL reflects its origin from germinal 
center B-cells, genes encoding cell cycle regulator proteins, transcription factors such as PAX-5 
and ID-2 and several proteins involved in microenvironment interaction (cytokines, cytokine 
receptors and cell adhesion molecules) are differentially expressed in FL and germinal center 
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derived B-cells (Husson et al, 2002;Piccaluga et al, 2008). The interaction with cells present in 
the tumor microenvironment is vital for the malignant B-cells of FL and FL-cells are difficult to 
culture in vitro. The composition of the FL microenvironment is associated with clinical 
outcome. A combination of two gene expression signatures reflecting the presence of T-cells 
and macrophages (immune response 1 and immune response 2) in the tumor, predicted FL 
survival (Dave et al, 2004). Several studies based on immunohistochemical and (phospho-)flow 
cytometry markers for different immune reported variations in the composition of the FL 
microenvironment with correlations to survival (see for instance (Farinha et al, 2005;Wahlin et 
al, 2007;Canioni et al, 2008;Taskinen et al, 2008;Farinha et al, 2010;Ame-Thomas et al, 
2012;Myklebust et al, 2013). Results are however, inconsistent and the prognostic significance 
of tumor infiltrating immune cells seems to be treatment dependent (Salles, 2007;de Jong & 
Fest, 2011;Gribben, 2010).  
Recent studies applying modern DNA deep sequencing techniques on FL genomes, 
detected frequent mutations in genes regulating histone modifications. EZH2 catalyze 
methylation of the histone 3 (H3K27) and thereby contributes to repressed transcription in loci 
associated with methylated H3K27. The result is epigenetic silencing of anti-proliferative genes 
in germinal center B-cells. Activating mutations in EZH2 is present in 20-30 % of FL cases (Morin 
et al, 2010;Velichutina et al, 2010;Yap et al, 2011;Bödör et al, 2013). MLL2 is also frequently 
targeted by inactivating mutations in FL. This histone methyltransferase with specificity for 
H3K4 and regulates transcription of developmental genes (Morin et al, 2011). Furthermore, the 
acetyltransferase CREBBP is frequently inactivated by mutations in FL (Green et al, 2013). The 
high frequency of mutations targeting genes involved in histone modifications indicate that 
epigenetic regulation of gene expression is an early event in FL lymphomagensis. 
The thesis papers 
A brief summary of the four included papers is given below. 
Paper 1 
The frequencies and pattern of cytogenetic aberrations occurring secondary to 
t(14;18)(q32;q21) in a series of 149 non-Hodgkin’s B-cell lymphomas were examined. The cases 
were retrieved from the archives at the Department for Medical Genetics at The Norwegian 
Radium Hospital. Cases with complete karyotype data based on G-banding and complete clinical 
information were selected for the analyses. Among the 149 samples 112 showed FL and 37 
DLBCL. Five of the FL samples showed FL grade 3b, three of which were obtained at primary 
diagnosis. Fifteen of the DLBCL samples originated from patients with a previous history of FL 
52 
 
(transformed from FL) and the remaining 22 were from patients with de novo DLBCL.  Secondary 
aberrations were observed in 140 of the samples (94%) with a median number of 6 aberrations 
per sample. Losses from chromosome arms 1p, 6q and trisomy 7 occurred most frequently in all 
samples. Losses from Xp, 1q, 14q, monosomy 16 and trisomy 12 were more frequent in de novo 
DLBCL and primary FL3b than in FL grade 1-3a, while loss from 6q was more frequent in FL grade 
1-3a. This indicates that subsequent to t(14;18)(q32;q21) the clonal evolution follows different 
paths in FL and de novo DLBCL. Loss from 1p was more frequent in FL grade 3a than in grade 1-2 
(p=0.049). Comparing FL-samples obtained before and after treatment, inversion of 
chromosome arm 6p and loss from 6q were more frequent after treatment (p=0.038 and 
p=0.011, respectively), indicating a selective advantage upon chemotherapy challenge for tumor 
cell clones bearing these aberrations. Comparing the FL samples (n=107) to the samples 
showing transformation (including 15 DLBCLs and 3 FL grade 3b from patients with previous FL 
grade 1-3a), loss from 14q, monosomy 15, trisomy 16 and trisomy 22 were more frequent in the 
transformed lymphoma samples (p=0.049, p=0.044, p=0.018 and p=0.04, respectively). This 
indicates that transformation is associated with clonal evolution and the appearance of certain 
secondary aberrations. The total number of secondary aberrations did not differ significantly in 
the two groups. No aberrations varied significantly in frequency among FL biopsies originating 
from patients showing histologic transformation during the observation time (n=33) and those 
without histologic transformation (n=74). In FL grade 1-3a, the presence of 6 or more 
aberrations and trisomy 21 correlated with inferior survival (p=0.0051 and p=0.0095, 
respectively). Gain of chromosome X was of borderline significance for inferior survival 
(p=0.067).   
Paper 2 
Forty-seven patients with histologically verified transformation from indolent B-cell lymphoma 
to DLBCL from five Norwegian centers were included between January 1999 and June 2004. All 
patients had previously received chemotherapy and the median time from primary diagnosis to 
inclusion was 41 months (range, 6-212). Only five had received rituximab prior to inclusion. The 
majority of patients responded to induction chemotherapy and 30 (63%) were treated by HD-
ASCT. Eighteen patients (60%) achieved CR, 7 (23%) PR and 5 (10%) had progressive disease 
following HD-ASCT. Median follow-up time for patients alive was 75 months. PFS rates at 2 and 
5 years were 50% (95% CI 0.32-0.68) and 32% (95% CI 0.18-0.46), respectively, while OS rates at 
2 and 5 years were 73% (95% CI 0.57-0.89) and 47% (95% CI 0.29-0.65), respectively. In all, 13 
patients relapsed after HD-ASCT. Median OS was only 10 months for the 17 patients not eligible 
for HD-ASCT. However, long term remission and survival was observed in three of these patients 
following either prolonged treatment with the induction regimen or radiation therapy. In vitro 
purging of the autologous stem cell graft was performed at one of the study centers. Patients 
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receiving CD34+ enriched/B-cell depleted grafts (n=10) had inferior PFS and a trend for inferior 
OS compared to patients receiving non-purged grafts (Log Rank 0.025 and 0.151, respectively). 
Patients with poor mobilization of stem cells to peripheral blood had inferior progression free 
survival compared to those with uncomplicated leukapheresis (p=0.025). Patients who had 
received 2 or more chemotherapy courses prior to inclusion had inferior PFS and OS (p=0.015 
and p=0.022, respectively).  In conclusion, the recommendation of HD-ASCT for patients with 
chemo-sensitive transformed lymphoma is reinforced by the study. However, the effect of HD-
ASCT needs to be assessed in patients who have received rituximab for indolent lymphoma prior 
to transformation. The study confirms that ex vivo purging of the autologous stem cell graft by 
current methods is not beneficial for patient survival. 
Paper 3 
The aim of the study was to examine the genetics of clonal evolution in FL and to identify 
genetic alterations associated with disease progression. DNA copy number alterations (CNAs) 
were assessed by arrayCGH in 100 biopsies from 44 patients diagnosed with t(14;18)-positive FL. 
In addition, the patterns of somatic hypermutations in the IgVH-loci were analyzed in samples 
from 20 of the patients. Complete and long-term clinical information was available for all 
patients. Nineteen patients developed histologically verified transformation to DLBCL. Eight 
additional patients showed clinical criteria for higher grade transformation as defined by Al-
Thourah et al (2008). The remaining 17 patients showed no signs of transformation.  
In initial biopsies, the most frequently recurring regions of chromosomal gain were 
Xp11q21 (57%), 1q22 (50%) and 18p11q21 (41%), while chromosomal loss occurred most 
frequently in 6q23q25 (27%), 1p36 (23%) and 13q34 (18%). A different pattern of recurring 
chromosomal imbalances were observed in initial biopsies from the cases with and without 
subsequent transformation; gains of chromosome 5, chromosome arms 2p and 3q were 
exclusively observed in the initial biopsies of FL from patients with transformation. In addition, 
gains of 12q13 and chromosome 21 were more frequent in FL-biopsies from cases with 
subsequent transformation (25% vs 13% and 25% vs 6%, respectively). Gain of X in male patients 
was the strongest predictor of inferior survival, gain of 2p, 3q, 5p, 5q and 12q were also 
associated with inferior survival. Thus, regions of gain associated with transformation and 
inferior survival showed considerable overlap.  
In 27 of the 39 cases with two or more biopsies, one or more of CNAs present in initial 
biopsies were absent in later relapse biopsies and in 24 of these new CNAs also appeared. This 
alteration in CNA profiles with time may reflect a parallel evolution of tumor cell clones. In 9 
cases, only the appearance of new CNAs was observed in relapse samples. In 3 cases the CNA 
profiles were without changes. In the 12 latter cases, the addition of new CNAs or unchanged 
CNA profiles may reflect a linear evolutionary path. Genealogical trees generated from the 
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patterns of SHM in IgVH-loci confirmed the frequent occurrence of parallel clonal evolution in 
the successive FL-biopsies. 
The level of CNAs as measured by the CNA index, showed a trend for increasing values in 
the last biopsies compared to the initial biopsies. However, the CNA index showed considerable 
variation with time at the individual level, also consistent with a parallel evolution of tumor cell 
clones. 
In conclusion, this study confirms the extensive intraclonal heterogeneity in FL cells and 
demonstrates that the evolutionary path of tumor cell clones is traceable at the whole genome 
level. Parallel evolution of tumor cell clones is common and indicates the existence of a FL 
precursor cell that may survive repeated treatment and give rise to clonally related, but 
genetically different relapse clone. This hypothesis is supported by the observation that the 
degree of genomic instability (as measured by the CNA index) varies considerably in successive 
FL-biopsies.  
Paper 4 
The study is based on the same sample material as in Paper 3, consisting of 100 sequential fresh 
frozen biopsies from 44 patients diagnosed with follicular lymphoma positive for the 
translocation t(14;18). In addition to the whole-genome copy number data described above, we 
obtained gene expression profiles from 81 of the samples originating from 41 patients. Analysis 
of the correlation between gene expression and DNA copy number indicated that a large 
number of genes are subject to gene dosage effect in FL. Genes with Pearson correlation 
between copy number and expression exceeding 0.4 and differential expression (p<0.05) in 
samples with gain (or in samples with loss) compared to samples with normal copy number 
were defined as cis-associated genes and selected for further analyses. By these stringent 
selection criteria, we identified 698 cis-associated genes. Interestingly, 23% of the cis-associated 
genes reside on chromosome X and the gain of X is associated with inferior survival in FL. An 
independent set of 191 FL samples with gene expression data and corresponding conventional 
CGH data from 131 samples was used to validate our findings. The 698 cis-genes also showed 
high positive correlations between copy number and gene expression in the independent set of 
131 FL samples. Pathway analyses revealed that the molecular network most enriched for these 
cis-associated genes included 14 mediators and regulators in the NF-ʃ ƐŝŐŶĂůŝŶŐ ƉĂƚŚǁĂǇ͘
Importantly, 12 of these 14 genes also showed cis-association between copy number and gene 
expression in the independent data set. For each of these 14 NF-ʃ ůŝŶŬĞĚ ĐŝƐ-genes, the 
correlated NF-ʃ ƚĂƌŐĞƚ ŐĞŶĞƐ ǁĞƌĞ ŝĚĞŶƚŝĨŝĞĚ͘ dŚŝƐ ƌĞƐƵůƚĞĚ ŝŶ ϭϰ ĚŝĨĨĞƌĞŶƚ ƐŝŐŶĂƚƵƌĞƐ ŽĨ
associated NF-ʃ ƚĂƌŐĞƚ ŐĞŶĞƐ ĂŶĚ ĐŽƌƌĞƐƉŽŶĚŝŶŐ ŐĞŶĞ ĞǆƉƌĞƐƐŝŽŶ ƐĐŽƌĞƐ ǁĞƌĞ ĚĞĨŝŶĞĚ ďǇ
averaging the gene expression in each signature. The correlations between NF-ʃ ůŝŶŬĞĚ ĐŝƐ-
genes and target genes were positively and significantly associated in our data set and the 
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independent set of 131 FL samples. The corresponding signature scores showed similar 
distribution patterns in the two data sets. For six of the NF-ʃ ůŝŶŬĞĚ ĐŝƐ-genes (BTK, IGBP1, 
IRAK1, ROCK1, TMED7-TICAM2 and TRIM37) the corresponding target gene scores were 
significantly associated with transformation. The strongest predictors for transformation were 
the IRAK1- and TRIM37 associated signature scores, high scores being associated with 
transformation. In particular, the predictive role of IRAK1, BTK and IGBP1 associated scores, 
suggests involvement of TLR- and BCR-signaling in transformation of FL. 
Discussion of material and methods 
Material in Paper 1; selection of tumor samples and patients 
The study presented in Paper 1 was a retrospective analysis designed to characterize secondary 
chromosomal aberrations occurring in lymphomas carrying the translocation t(14;18)(q32;q21).  
Among the 149 included samples, 112 showed FL and 37 DLBCL. Five of the FL samples 
showed FL grade 3b, three of which were obtained at primary diagnosis. Among the samples 
showing FL grade 1-3a, 47 were obtained at primary diagnosis. Fifteen of the DLBCL samples 
originated from patients with a previous history of FL (transformed from FL) and the remaining 
22 were from patients with de novo DLBCL. These numbers of DLBCL samples deviate from 
those given in Paper 1, as two FL 3b samples were lumped together with the transformed 
DLBCLs and three with the de novo DLBCLs (Paper 1 page 457). In retrospect, the grouping of 
transformed DLBCL and de novo DLBCL together (also with FL3b) in some of the analyses for 
subtype comparisons and clinical associations is not justified, as these are biological distinct 
entities and have different clinical courses. It also seems more correct to leave the FL grade 3b 
out of the analyses. 
As karyotyping requires the preparation of cell suspensions from fresh tumor tissue and 
culturing of tumor cells in vitro, not all specimens obtained for diagnostic purposes could be 
karyotyped. A bias for larger samples obtained from peripheral nodes is likely. In addition, 
especially FL may be difficult to culture in vitro and a bias for examining tumor cell clones that 
are less dependent on the microenvironment of the lymph node may be introduced. 
Clinical information was retrieved from the lymphoma data base at our institution in 
which data about all referred lymphoma patients have been collected prospectively since 1980. 
Our center is a regional referral center for lymphomas and has been the largest in the Nordic 
countries for a long time. Thus, the clinical database contains data from a relatively unselected 
patient population. Although many of the patients referred to our center are included in clinical 
studies, selected cases for this study were subject to different treatment regimens. 
Furthermore, the trends in lymphoma treatment changed during the 1990s (for instance less 
use of chlorambucile in FL and advent of rituximab for both DLBCL and FL).  
56 
 
The number of included de novo DLBCL is somewhat lower than expected. According to 
our clinical database more than 700 patients have been treated for DLBCL since 1980, and 20-
30% of these are expected to harbor the translocation t(14;18). As diagnostic samples often are 
needle biopsies of retroperitoneal masses it may not have been sufficient material for 
karyotyping in many of the DLBCL-cases. The few de novo DLBCL cases hamper robust clinical 
correlations in this group. 
A relatively high number of FLs were included and the analyses of these confirmed 
previous findings such as the distribution of FLIPI-score, the impact of FLIPI-score on survival, 
the inferior survival in FL-patients with subsequent transformation, the association between 
inferior survival and a high total number of chromosomal aberrations, as well as the association 
between inferior survival and gain of X. In addition, we observed that gain of 21 is associated 
with inferior survival in FL.  
As follicular lymphoma comprises the largest group of cases in Paper 1 and is the main 
focus in Paper 2-4, the following discussion of results from Paper 1 will focus this lymphoma 
entity. 
Material in Paper 2; patient inclusion  
The study presented in Paper 2 was designed as a prospective national multicenter study 
to make the patient sample as representative as possible for patients younger than 65 years. 
According to national guidelines all patients that are diagnosed with transformed FL should be 
referred to one of the four University Hospitals with facilities for ASCT. All four centers 
performing ASCT in Norway participated in the study. In clinical practice today, the upper age 
limit for HD-ASCT is not as absolute and patients aged above 65 may also be offered HD-ASCT if 
they are in good condition with minimal co-morbidity. As FL with transformation is a relatively 
uncommon disease it was not possible to perform a randomized study including patients in a 
control group. Instead, data were compared to published historical data. Patients were included 
at start of salvage chemotherapy for transformed FL so that the prognosis for the whole cohort 
of patients was available. In addition, this allowed unbiased comparison of outcome for those 
who were eligible for HD-ASCT and those who were not. 
The study was planned to include 100 patients. Assuming a 70% response rate to salvage 
chemotherapy, 100 patients will give a 95% confidence interval (CI) of +/- 9%. If the 70 patients 
completing HD-ASCT have a three year OS of 50% and PFS of 30%, the CI will be +/- 12% and 
11%, respectively. Due to the introduction of rituximab in the salvage treatment of patients with 
transformed B-cell non-Hodgkins lymphomas, the study was closed before this number was 
reached. The early closing results in wider 95% confidence intervals than expected for the 
estimated survival rates at 2 and 5 years, thus the conclusions are less robust than they would 
have been with more patients. 
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Originally, a total of 68 patients were included between January 1999 and July 2004 
based on the diagnosis of either DLBCL or FL grade 3 at study entry. They all received induction 
chemotherapy with the intention to test chemosensitivity prior to HD-ASCT. Forty-four of the 68 
went on to HD-ASCT. Data from 47 of the 68 patients were analyzed and reported in Paper 2. 
Four cases were excluded from the final analyses due to altered diagnosis from DLBCL at study 
entry to diffuse FL at central review. The remainder of excluded patients had the diagnosis FL 
grade 3 at study entry or at central review. 
The clinical relevance of FL grading has been debated since the 1980ies. The present 
system for grading as defined in the latest WHO classification, had been linked to patient 
outcome in a number of studies prior to 1999 (Martin et al, 1995) showing inferior outcome for 
patients presenting with FL grade 3 at diagnosis compared to patients with FL grade 1-2. On the 
basis of these studies many centers, including ours, treated patients with FL grade 3 with 
intensified chemotherapy regimens more like the treatment for DLBCL. Progression from FL 
grade 1-2 in a primary biopsy to grade 3 at relapse was by many clinicians considered as higher 
grade transformation and treated thereafter.  
During the inclusion time of our study data supporting a subdivision between FL grade 
3a and 3 b was published, as discussed in the above section “Treatment of transformed 
lymphoma”.  
In conclusion, the 47 patients included in the analyses presented in Paper 2 are likely to 
be highly representative for the population of patients with histologic transformation younger 
than 65 years treated in the pre-rituximab era. 
 
Material in Paper 3 and 4; selection of samples and patients 
The studies presented in Paper 3 and 4 were retrospective analyses designed to detect genetic 
alterations occurring in the relapse of FL and correlate these to clinical outcome. Along with the 
detailed and long-term clinical follow-up data, we believe that this tumor sample material is 
unique in representing FL in a longitudinal perspective and well suited for addressing the 
molecular dynamics of this disease. 
For 100 biopsies collected between 1987 and 2005 originating from 44 patients there 
was sufficient material for DNA extraction and arrayCGH analyses (Paper 3). For 81 of these 
biopsies originating from 41 of the same patients, there was also sufficient material for mRNA 
extraction and gene expression analyses (Paper 4).  
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 Number of biopsies per patient  
Total number of patients Type of data 1 2 3 4 
DNA copy number 5 24 13 2 44 
Gene expression 8 27 5 1 41 
 
 
Table 3. Data sets used in Paper 3 and 4. The four middle columns show how many of the 
patients that were represented by DNA copy number data and gene expression data from 1, 2, 3 
and 4 biopsies. 
 
 
Karyotypic data were available from 89 of the biopsies and showed the presence of 
t(14;18)(q32;q21) in at least one biopsy from each of the 44 patients. The karyotypes of the first 
biopsy from 40 of the patients were included in the study presented in Paper 1. 
In theory, the selection of serial biopsies of FL may introduce a bias for patients with 
prolonged survival. Patients with transformation were, however, well represented with their 
respective FL-biopses in our material, even if few biopsies showing transformation to DLBCL 
were included. Furthermore, we have practiced liberal indications for biopsy at progression or 
relapse of FL at our institution. The detailed clinical information retrieved from the lymphoma 
database and from individual patient files was of great value in this study and the distribution of 
clinical parameters indicate that the included patients are representative for the population of 
FL patients diagnosed in the pre-rituximab era. We therefore believe that in practice this bias is 
minor.  
The patients were treated according to national guidelines. The treatment of FL patients 
is based on individual evaluation and especially for relapses the patients had received 
heterogeneous treatment. For instance, 14 patients received HD-ASCT; nine due to 
transformation to DLBCL and 5 due to progression to FL grade 3a (which was treated more 
aggressively than FL grade 1-2 prior to 2005). In all, 23 patients received rituximab during the 
observation time; 3 at initial treatment and 20 at relapse. The proportion of patients receiving 
rituximab was equal among patients with and without transformation (уϱϬй ŝŶďŽƚŚŐƌŽƵƉƐͿ͘
There was no difference in overall survival between patients receiving and not receiving 
rituximab. Theoretically, differential treatment may influence the clonal selection and molecular 
features of the tumors and may thus complicate interpretation of clinical correlations. The vast 
majority of FL patients today receive rituximab both in first line treatment and as part of the 
treatment at relapse. Prognostic markers identified in patients in pre-rituximab era may not be 
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directly applicable to patients today and the findings in our studies need to be validated in new 
patient cohorts. 
In the planning of this study, we decided to focus on the genetics in relapsing FL and 
archived biopsies showing transformation to DLBCL were omitted, except for 9 cases where the 
histology had been ambiguous prior to the review performed for this study. In retrospect, it 
becomes clear that inclusion of as many transformed biopsies as possible would have been of 
value to obtain a deeper insight to the clonal diversity in FL as well as the biology of 
transformation. This will be addressed in following studies. 
Choice of method for quantification of DNA copy number (Paper 3 and 4) 
Karyotyping by chromosome banding was introduced by the Swedish geneticist Torbjörn 
Caspersson and his colleagues in 1970. In human cytogenetics G-banding is a commonly used 
technique in which metaphase chromosomes are stained with Giemsa. This results in transverse 
dark bands in heterochromatic and A-T-rich regions and light bands in the G-C-rich euchromatic 
regions. Each chromosome can then be identified by a unique pattern of transverse bands. G-
banding was used to obtain the cytogenetic data presented in Paper 1. The method allows 
detection of both chromosomal imbalances and structural aberrations at a resolution of 5-8 Mb. 
The method is time-consuming and the preparation and accurate interpretation of the G-
banded metaphase spreads requires long experience. In tumor genomes with complex 
karyotypes the exact chromosomal origin of displaced genomic material can be difficult to 
determine. Multicolor-FISH may then be useful to examine more closely selected cases and was 
applied for a subset of samples in Paper 1.   
Array comparative genomic hybridization (arrayCGH) is a powerful tool for simultaneous 
quantification of DNA copy number at thousands (or even millions) of genomic loci. Several 
microarray technologies are available (see below). Among other things, the source of the 
probes, the distribution and density of probes per gene or chromosome differs substantially 
between platforms. Some major technologies for high throughput copy number assessment are: 
x BAC/PAC arrays: The probes are DNA constructs cloned in E.coli by the use of bacterial 
plasmids; F-plasmid and P1-plasmid for the cloning of Bacterial Artificial Chromosomes 
(BAC) and P1-derived Artificial Chromosomes (PAC), respectively.  The probes are 
spotted in grids onto glass slides which serve as the platform for competitive 
hybridization of differently labeled sample DNA and reference DNA (Figure 12). The 
probes represent the human genome at variable intervals; the early arrays contained 
уϯϱϬϬƉƌŽďĞƐǁŝƚŚƚŚĞĂǀĞƌĂŐĞůĞŶŐƚŚŽĨϭϱϬ-350 kb at intervals of approximately 1 Mb 
along the human genome. In modern arrays уϯϮϬϬϬƉƌŽďĞƐĂƌĞƉůĂĐĞĚ ŝŶĂ ƚŝůŝŶŐƉĂ th 
along the interrogated genome enabling the detection of smaller genomic lesions 
(theoretically down to the size of 50k) (Solinas-Toldo et al, 1997;Pinkel et al, 
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1998;Snijders et al, 2001;Fiegler et al, 2003;Ishkanian et al, 2004). The BAC/PAC arrays 
returns the average DNA copy number from the cells in the sample relative to a normal 
reference. Balanced chromosomal rearrangements are not detected. In chromosomal 
CGH, a spread of normal human metaphase chromosomes is used as the platform for 
hybridization instead of BAC clones printed on glass. This method preceded the 
development of array based technologies.  
 
x cDNA arrays: The probes are complementary DNA synthesized from mature mRNA by 
the use of the enzyme reverse transcriptase. Thus, cDNA probes represent the coding 
regions of the human genome and the arrays are suited for gene expression profiling. 
However, they have also been widely used to interrogate DNA copy number; see for 
instance (Pollack et al, 2002).  
 
x Oligo arrays: The probes are long (60 mer) or short (25 mer) oligonucleotides; see for 
instance (Bignell et al, 2004), which are synthesized in situ on the array platform (which 
may be either a chip or beads). The arrays may contain millions of probes representing 
both coding and non-coding regions of the human genome, including SNPs (single 
nucleotide polymorphisms) and CNPs (copy number polymorphisms).  
 
x SNP arrays: Neither of the platforms above allows detection of balanced genomic 
rearrangements, loss of heterocygozity/acquired uniparental disomy (aUPD) or the 
determination of ploidy or tumor cell percentage. SNP arrays are a special type of oligo 
arrays that focus on SNP loci, or a combination of SNP loci and other loci. For each SNP 
locus, both alleles are measured, thus generating allele specific copy number data. This 
allows the estimation of tumor cell percentage, ploidy and identification of aUPD (Van et 
al, 2010). Such arrays were originally designed for SNP genotyping of germline DNA, but 
are currently widely used to examine somatically acquired genomic lesions. 
In this thesis (Paper 3 and 4), in-house BAC/PAC arrays were used to obtain DNA copy number 
data from the serial biopsies of FL. The arrays were produced in a core facility at our institution 
(Meza-Zepeda et al, 2006) and contained уϰϱϬϬƉƌŽďĞƐƉƌŝŶƚĞĚ ŝŶƋƵĂĚƌƵƉůŝĐĂƚĞ ƌĞƉƌĞƐĞŶƚŝŶŐ
the human genome at intervals of approximately 1 Mb. The tumor DNA and a commercially 
available sex matched reference DNA were labeled with Cy3 and Cy5, respectively, and co-
hybridized to the slides. Following scanning of the slides, the images were segmented, raw data 
was filtered and log2-ratios were calculated using GenePix 6.0 Simple.  
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Gene-expression analysis (Paper 4) 
The Affymetrix HG U133 Plus 2.0 Gene Chip® was applied to obtain gene expression profiles for 
81 of the serial biopsies. The array contains short oligonucleotide probes (25-mer), synthesized 
in situ on the array, representing more than 47 000 gene transcripts, including > 38 000 well-
characterized genes. On the array there is also a set of control probes representing sequences 
for quality control assessment (hybridization control, poly-A controls, normalization controls 
and housekeeping genes). Each sample is labeled individually and hybridized to a single array. 
The Gene Chip® is a single-color array  and the estimated gene expression level of each 
transcript is reported as a single fluorescent intensity (not a ratio) (Quackenbush, 2006).   
To map the expression probes to the respective genomic position we applied the 
annotation file (HG-U133_Plus_2.na27.annot.csv) supplied by Affymetrix and selected the 
probes with unique Entrez ID and an exact genomic location. The original set of 51k expression 
probes was thus reduced to 21k. 
Figure 13. Array comparative genomic hybridization (arrayCGH) workflow. ArrayCGH exploits 
the intrinsic property of DNA to denature to single strands upon heating which hybridize to 
restore a double stranded helix upon cooling. Tumor DNA and a sex matched reference DNA 
are labeled with fluorescent Cy3 and Cy5, respectively. In cycles of heating and cooling the 
sample and reference DNA compete to hybridize with the complementary DNA of the BAC and 
PAC probes on the glass slide. After washing the slides are scanned and the relative fluorescent 
intensities are analyzed.
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Choice of statistical methods (Paper 3 and 4) 
The Cy3/Cy5-ratios (Figure 12) from arrayCGH are usually first log2-transformed and normalized 
and then segmented in order to determine the genomic loci where the copy number is altered. 
In this thesis, simple mean local normalization was applied to the log2-transformed arrayCGH 
measurements. Each subgrid of the array is then normalized separately. The intensity ratio of 
each probe spot is multiplied with a factor equal to the ratio of the mean dye intensities in all 
spots in the respective subgrid (Beheshti et al, 2003).  
Several methods for copy number segmentation exist, including circular binary 
segmentation (Venkatraman & Olshen, 2007), aCGHsmooth (Picard et al, 2005) and piecewise 
constant fitting (PCF) (Nilsen et al, 2012). In this thesis, PCF was used for all segmentations. This 
method fits a piecewise constant function to the copy number profile by minimizing a penalized 
ůĞĂƐƚ ƐƋƵĂƌĞƐ ĐƌŝƚĞƌŝŽŶ ŽĨ ƚŚĞ ĨŽƌŵ  с  н ɶW͕ ǁŚĞƌĞ  ŝƐ ƚŚĞ ŐŽŽĚŶĞƐƐ ŽĨ Ĩŝƚ ƚŽ ƚŚĞ ĚĂƚĂ
(represented by a sum of squared residuals) and P is the number of segments in a solution. The 
ƉĂƌĂŵĞƚĞƌ ɶхϬ ĚĞƚĞƌŵŝŶĞƐ ƚŚĞ ƚƌĂĚĞ-off between the two terms, and was set low in our 
analyses to provide a sensitive detection of breakpoints. PCF is implemented in the 
Bioconductor package copynumber and offers various options, including an algorithm for 
segmentation of a single array at a time (pcf) and an algorithm for simultaneous segmentation 
of several arrays (multipcf), thus resulting in a common set of breakpoints across the arrays. 
Both algorithms were used in this thesis.  
The result of the copy number segmentation is a set of break points, or equivalently a 
division of the genome into a number of segments, each with constant copy number. For each 
segment, the estimated copy number level is the average log2Ratio value for all probes on that 
segment. To call copy number aberrations, Ă ƚŚƌĞƐŚŽůĚ ɽхϬ ŝƐ ĚĞĨŝŶĞĚ͘ ll genomic loci with 
estimated copy number level below –ɽĂƌĞĐĂůůĞĚĂƐ ůŽƐƐĞƐ͕ǁŚŝůĞĂůů ůŽĐŝǁŝƚŚĞƐƚŝŵĂƚĞĚĐŽƉǇ
ŶƵŵďĞƌ ůĞǀĞů ĂďŽǀĞ ɽ ĂƌĞ ĐĂůůĞĚ ĂƐ ŐĂŝŶƐ͘ dŚĞ ƉĂƌĂŵĞƚĞƌ ɽ ĐŽŶƚƌŽůƐ ƚŚĞ ƚƌĂĚĞ-off between 
ƐĞŶƐŝƚŝǀŝƚǇĂŶĚƐƉĞĐŝĨŝĐŝƚǇŽĨƚŚĞĐŽƉǇŶƵŵďĞƌĐĂůůŝŶŐ͘ƐɽŝŶĐƌĞĂƐĞƐ͕ĨĞǁĞƌƐĞŐŵĞŶƚƐĂƌĞĐĂůůĞĚ
as aberrant. This results in a decrease in sensitivity (fewer real aberrations are called) and an 
increase in specificity (fewer false aberrations are called). In practice, the appropriate selection 
ŽĨ ɽ ĚĞƉĞŶĚƐ ŽŶ ƚŚĞ ƉůĂƚĨŽƌŵ ƵƐĞĚ ĂŶĚ ƚŚĞ ĂƌƌĂǇ ƋƵĂůŝƚǇ͘ &ƵƌƚŚĞƌŵŽƌĞ͕ ŝƚ ĚĞƉĞŶĚƐ ŽŶ ǁŚĂƚ
biological features in the sample one wants to detect. In particular, in a sample consisting of a 
mixture of cells with different genetic constitution the signal from each cell subpopulation will 
be smaller. As previously discussed, the relative proportion of tumor cells versus cells with 
normal copy number differs between FL biopsies. To capture copy number aberrations also in 
ƐĂŵƉůĞƐǁŝƚŚůŽǁƚƵŵŽƌĐĞůůƉĞƌĐĞŶƚĂŐĞ͕ƚŚĞƚŚƌĞƐŚŽůĚɽǁĂƐƐĞƚƚŽƌĞůĂƚŝǀĞůǇŚŝŐŚƐĞŶƐŝƚŝǀŝƚǇŝŶ
Paper 3 and 4. Comparison of copy number calls in sequential biopsies with variable tumor cell 
percentage from the same individual confirmed that the chosen threshold was adequate (data 
not shown). 
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To measure the total extent of copy number alterations in a sample, we defined a score 
(CNA-index) that counts the number of aberrant probes, weighing each by the magnitude of 
aberration. This was used as a marker for genomic instability. The presence of balanced 
genomic aberrations other than t(14;18) and aUPDs also occur in FL and reflect genomic 
instability. These are not detected by the arrayCGH, and are therefore not counted for by the 
CNA-index. The CNA-index may be influenced by the number of tumor cells relative to the 
normal cells in the sample material. There may be a bias for higher CNA-index in samples with 
high tumor cell content relative to infiltrating normal cells, although this was tested and found 
to be minimal and we believe the CNA-index correlates well with genomic instability.  
To correlate DNA copy number data derived from the BAC/PAC arrays containing 3091 
probes and the gene expression data from 21k annotated genes, the PCF-values were 
interpolated so that each expression probe was matched to a corresponding PCF-value. 
Thousands of the genes represented on the gene expression array lie in genomic regions that 
are not covered by a probe on the arrayCGH. PCF estimates DNA copy number from several 
adjacent BAC probes and thus, provide robust copy number estimates for all genes within an 
aberrant (or normal) genomic segment. Genomic breakpoints were assumed to be placed in the 
middle between the flanking BAC probes and PCF segments were interpolated. Thus, for genes 
located close to genomic breakpoints, the estimate for copy number may be inaccurate. 
To examine the presence of known oncogenes and tumor suppressor genes among the 
698 cis-genes we performed pathway analyses in Ingenuity Systems Pathway Analysis tool (IPA). 
This is one of several tools available for pathway analysis and is based on a statistical gene set 
enrichment analysis. Gene set enrichment analyses have increased power to detect effects on 
gene set level and facilitates the interpretation of results from high-throughput analyses of gene 
expression. In such analyses, the genes of interest are compared to predefined sets of genes to 
investigate functional relationships. The predefined gene sets can be molecular interaction 
networks or biological functional categories of genes. The IPA tool is based on a manually 
curated knowledge database (Ingenuity Knowledge Database®).  
Comparisons of survival in different groups of patients were carried out using Kaplan-
Meier curves and log-rank tests. Differences in CNA-indexes were tested by variance component 
models. The impact of chromosomal gains or losses on survival was assessed by Cox’s 
proportional hazards regression. For each biopsy, one or more copy number features are 
observed and related to survival. In this thesis, multipcf was used to define these features, and 
univariate Cox regression was then used to assess the association between survival and each 
feature individually. The association between gene-expression scores as defined in Paper 4 and 
transformation was assessed by Student’s t-test and logistic regression. 
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General discussion of results and future perspectives 
Treatment of transformed FL 
Higher grade transformation is associated with a dramatic reduction in overall survival times, as 
shown in Paper 1 and 3. In the Canadian population based study by Al-Tourah et al (Al-Tourah et 
al, 2008) the 10 year survival rates for patients with and without transformation rates were 36% 
and 75 %, respectively, which is similar to our findings. In the same retrospective study the 
median survival following transformation was only 1.7 years. The majority of patients included 
in Paper 1, 3 and 4 was treated in the pre-rituximab era and received CHOP-like regimens. The 
poor outcome of transformed FL following treatment by standard chemotherapy regimens 
motivated the study presented in Paper 2. The effect of HD-ASCT for patients with 
transformation from indolent B-cell lymphoma to DLBCL was assessed in a multicenter 
prospective study.  
A high response rate to induction chemotherapy was achieved and 63% of included 
patients were treated by HD-ASCT. The response rate to HD-ASCT exceeded 80% (CR and PR). 
PFS rates at 2 and 5 years were 50% (95% CI 0.32-0.68) and 32% (95% CI 0.18-0.46), 
respectively, while OS rates at 2 and 5 years were 73% (95% CI 0.57-0.89) and 47% (95% CI 0.29-
0.65), respectively. Prior to 1999, the year of the opening of this clinical study, a few limited 
sized retrospective studies had indicated that a subgroup of patients with chemo-sensitive 
disease obtains long-term survival following HD-ASCT for transformed indolent B-cell 
lymphoma. The prospective phase II trial presented in Paper 2 confirmed the benefit of HD-
ASCT in the group of patients with chemo-sensitive disease. In particular, we showed that many 
of the patients that obtained partial remission from induction treatment were brought into 
complete remission by HD-ASCT. The possible benefit of HD-ASCT is assessed with comparison 
to historical data (Yuen et al, 1995;Bastion et al, 1997;Gine et al, 2006;Montoto et al, 2007;Al-
Tourah et al, 2008). Ideally, a randomized study with conventional treatment as the standard 
would give a more definite answer, but has not been performed due to the rarity of the 
condition. 
The study was initiated and conducted before rituximab became part of the standard 
treatment for follicular lymphoma. Only five patients had received rituximab prior to study 
entry and Rituximab was not a part of the induction regimen. Four patients received one course 
of Rituximab before stem cell harvesting for in vivo purging of the stem cell graft. Interestingly, 
these four patients were among those with the longest survival following HD-ASCT, indicating 
that addition of rituximab in salvage regimens improves outcome of HD-ASCT in rituximab naïve 
patients. In a recent study by the Canadian Blood and Marrow Transplant group the 5-year PFS 
and OS were 55% and 65 %, respectively (Villa et al, 2013). In this study all patients received 
rituximab as part of the induction treatment prior to HD-ASCT, which may explain the 
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superiority of their results. The effect of rituximab is difficult to evaluate however, as the 
number of patients receiving rituximab for FL prior to transformation was not reported. In a 
recent study from Holland, the patients who had been treated with rituximab previous to 
transformation and HD-ASCT had inferior survival compared to patients that were rituximab-
naïve at transformation and HD-ASCT (Ban-Hoefen et al, 2011). 
There was no early treatment-related mortality and no patients developed secondary 
myelodysplastic syndrome. The study confirmed the safety of HD-ASCT for patients with 
transformed follicular lymphoma younger than 65 years. The procedure related mortality rate 
has dropped substantially from the mid 1980’ies (10-15%) till today (approximately 1%). This 
drop is most probably due to (i) a shorter cytopenia duration after introduction of blood derived 
rather than bone marrow derived haematopoietic stem cell support, (ii) better patient selection 
and (iii) improved supportive care during aplasia. In an unpublished series of all 711 Norwegian 
lymphoma patients undergoing HD-ASCT since 1987 until 2008, 10 year overall survival is 55%, 
ranging from 45% to 75% for the various entities. For many of the entities, there are few deaths 
beyond 5 years after HD-ASCT, indicating that a high percentage of these patients are cured 
from their disease. 
The survival of patients with indolent B-cell lymphoma has improved substantially during 
recent years. Data from our institution clearly demonstrates this positive trend (Figure 8) which 
is in line with published data from international centers (Fisher et al, 2005;Swenson et al, 
2005;Hiddemann et al, 2007;Hiddemann et al, 2005). The improved progression free and overall 
survival is largely due to the introduction of rituximab in the treatment of B-cell lymphomas. 
Rituximab has been used in combination with chemotherapy for more than 10 years in Norway. 
It is still not approved by the Medical Agencies in Norway as monotherapy in first line, although 
some studies have shown good responses and long-lasting remissions in patients with mild 
symptoms and low tumor burden (Colombat et al, 2012). First line rituximab monotherapy is 
currently being compared to novel combination regimens in recent and ongoing clinical trials, 
i.e. Nordic lymphoma group (NLG) trials M39065 (ref), ML16865: rituximab versus rituximab + 
interferon (ClinicalTrials.gov Identifier: NCT01609010); SAKK/NLG: rituximab versus rituximab + 
lenalidomide (ClinicalTrials.gov Identifier: NCT01145495). 
Whether or not HD-ASCT remains a good treatment approach for patients with 
transformed indolent B-cell lymphoma in the rituximab era needs to be addressed. We have 
recently performed a retrospective study investigating the outcome for patients with 
transformed indolent B-cell lymphoma in the present treatment era, including all patients 
referred to our institution with this diagnosis between 2005 and 2011 (Blaker YN et al, accepted 
in Leukemia and Lymphoma). A total of 42 patients aged 18-65 were considered for HD-ASCT in 
this period, all received induction chemotherapy including rituximab and 28 completed HD-
ASCT. The patients that were rituximab-naïve prior to study entry had significantly better OS 
after HD-ASCT than the patients who had already received rituximab (n=11 versus n=17, 
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p=0.039 in Log rank test), in line with results from a recently published smaller study by Ban-
Hoefen et al, 2012. The overall survival following HD-ASCT in our recent patient cohort was 
similar to the OS observed in Paper 2, indicating that HD-ASCT remains an efficient and safe 
treatment option for these patients. Whether or not prior rituximab treatment contributes to 
poorer induction response needs to be addressed in larger patient cohorts. Does previous 
treatment with ritiximab impact chemo-sensitivity as it does in relapsed de novo DLBCL 
(Gisselbrecht et al, 2010)? Novel approaches to achieve higher induction response rates in 
rituximab treated patients may improve outcome following HD-ASCT; for instance the 
replacement of rituximab with ofatumumab (Czuczman et al, 2012) the addition of lenalidomide 
(Czuczman et al, 2011), radioimmunotherapy (Gopal et al, 2007) or inhibitors of Bcl-2, PI3-
kinase and BTK (Advani et al, 2013;Sawas et al, 2011;Young & Staudt, 2013).  
Secondary chromosomal aberrations in FL and association to survival and 
transformation  
The tumor genome of FL is commonly hyperdiploid with low level gains recurrently involving 1q, 
2p, 5q, 6p, 7, 8q24, 12q, 17q, 18, 21 and X and recurrent losses involving 1p,  6q and 13q. The 
pattern of recurrent gains and losses as identified by arrayCGH in initial FL samples (Paper 3) 
and by karyotypic data (Paper 1) were in line with the previous studies (Yunis et al, 
1987;Hoglund et al, 2004;d'Amore et al, 2008;Horsman et al, 2001;Leich et al, 2009). 
Recent studies using high resolution SNP arrays have confirmed the frequency pattern of 
copy number alterations in FL (Bouska et al, 2013). This study also identified small aberrations at 
the peaks of the larger commonly aberrant regions and these small aberrations pinpoint a few 
candidate target genes. Studies using SNP array also enables detection of acquired uniparental 
disomy (aUPD) which  commonly involve 1p36, 6p21, 12q21-q24 and 16p13 (Fitzgibbon et al, 
2007;Ross et al, 2007;O'Shea et al, 2009;Cheung et al, 2010;Bouska et al, 2013). The aUPDs of 
6p21, 12q and 16p13 overlap with genomic regions that are commonly targeted by copy 
number gain, while 1p36 is frequently targeted by loss in FL, suggesting a selection in favor of a 
particular genotype in these regions. In the study by the Canadian group from 2012 (Cheung et 
al, 2012), aUPDs in these four regions were frequently observed in cases of t(14;18) positive FLs 
with a simple karyotype (harboring none or only one secondary aberration detected by 
karyotyping). This suggests that aUPDs are early genomic events in the pathogenesis of FL. 
In Paper 1 and 3 we assessed the association between secondary genomic aberrations 
and overall survival. Although the patient materials in the two studies partly overlap, the results 
are somewhat different. Possible explanations for this are (i) more patients with FL were 
included in Paper 1 than in Paper 3 (107 vs 44), (ii) copy number alterations were detected at a 
higher genomic resolution in Paper 3 than in Paper 1 (arrayCGH versus karyotyping) and (iii) the 
definition of transformation differs in the two studies; while only histological transformation is 
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considered in Paper 1, cases with clinical signs of transformation and histological transformation 
are grouped together in Paper 2. 
In Paper 3 gain of X in male patients was identified as the strongest predictor of inferior 
outcome. More specifically, high amplitude (pcf value) of the most commonly gained segment 
of X (chromosomal arm Xp) was associated with increased risk of death. In Paper 1 the 
association between an extra copy of X and inferior survival was only borderline significant. A 
higher frequency of gain of X was found in Paper 3 than in Paper 1 and this may be due to the 
more sensitive detection copy number aberrations by arrayCGH compared to karyotyping.  The 
prognostic significance of gain of X has previously been shown in a study by Johnson et al 2008 
(Johnson et al, 2008). In addition, gain of X was found to be associated with poor outcome in a 
study by Høglund et al 2004, but only in the univariate analysis. Viardot et al 2002 found a trend 
for poorer survival in patients with gain of Xq (Viardot et al, 2002). Many studies of genomic 
alterations in FL do not report clinical data and some of the CHG and SNP array studies do not 
report data on chromosome X (Cheung et al, 2008;Schwaenen et al, 2009;O'Shea et al, 2009). 
One reason for the latter may be the need for sex matched reference DNA to identify CNAs 
involving the sex chromosomes. Another challenge especially with chromosomal CGH is the 
relatively large proportion of heterochromatine on chromosome X, which may cause unspecific 
hybridization. Even when using reliable probe sets specific for chromosome X and a sex 
matched reference, the copy number values of chromosome X are sex biased, as gain of one 
copy results in a relatively higher LogRatio in male samples than in female samples. Whether 
the tumor biological consequence of gain of X differs in female and male patients remains 
unknown. Interestingly, in a study examining the methylation status of chromosome X, it was 
shown that the extra copy of chromosome X is active in male tumor samples while it can be 
either active or inactive in female samples (McDonald et al, 2000). We believe that our findings 
related to the gain of X are reliable and of importance for the deeper understanding of FL 
pathogenesis. Interestingly, a very recent study of high resolution copy number data in FL and 
transformed FL confirms that gain of X predicts patient outcome in FL (Bouska et al, 2013). 
In addition to gain of X, gain of 2p, 3q, 5p, 5q and 12q were found to be more weakly 
associated with inferior survival in Paper 3. Comparing initial FL samples from cases with and 
without subsequent transformation, we also observed that gain of 2p, 3q and 5 were exclusively 
present in the transformation group, while gain of 12q and chr 21 occurred more frequently in 
the this group than in the group without transformation. Gains of 2p, 3q, 5 and 12q have been 
associated with aggressive clinical and histopathological features in previous studies (Yunis et al, 
1987;Cheung et al, 2008;Johnson et al, 2008;Schwaenen et al, 2009;Hough et al, 2001). In a 
recent study by Bouska et al (Bouska et al, 2013) using SNP array the associations between gain 
of 3q, transformation and inferior survival was confirmed. Gain of chromosome 3 is associated 
with the more aggressive ABC-subtype of DLBCL and not the GCB-subtype (Bea et al, 
2005;Tagawa et al, 2005). The different patterns of recurring chromosomal imbalances in initial 
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biopsies from cases with and without subsequent transformation, indicates divergent 
evolutionary pathways and different pathogenic mechanisms in the FLs that remain FL and the 
FLs that are prone to higher-grade transformation. The transformation-associated aberrations 
each occur in small subsets of patients, suggesting that the mechanisms for transformation are 
heterogeneous. This is consistent with previous findings in studies including gene-expression 
studies of paired pre- and post transformation samples (Martinez-Climent et al, 2003;Elenitoba-
Johnson et al, 2003;Lossos et al, 2002;Davies et al, 2007). In Paper 1, trisomy 21 was associated 
with inferior survival in FL and no specific aberrations occurred with different frequencies in FL 
biopsies from patients with or without subsequent transformation. The association between 
gain of 2p, 3q and 5 was not assessed in Paper 1, as these aberrations occurred in less than 10% 
of cases.  
No regions of genomic loss were significantly associated with FL survival or 
transformation risk. Others have reported associations between inferior survival and loss of 
1p36, 6q21q24, 6q25q27 and 17p (Tilly et al, 1994;Viardot et al, 2002;Lestou et al, 
2003;Hoglund et al, 2004;Cheung et al, 2008;d'Amore et al, 2008). In the recent study by the 
LLMPP cooperation loss of 6q predicted outcome in a large series of FL and transformed FL 
samples (Bouska et al, 2013).The reason for lack of significant associations between losses and 
survival in Paper 3 may be the low number of patients. 
In Paper 1, the degree of genomic instability was assessed by counting the number of 
different breakpoints and the number of gains/losses of entire chromosomes. An increasing 
number of aberrations were associated with inferior survival. In Paper 3 we defined a marker 
for genomic instability, the CNA-index, and there was a trend for poorer survival with increasing 
CNA-index in initial FL samples, although not statistically significant. While the method applied 
in Paper 1 also counts balanced chromosomal aberrations (translocations and inversions), these 
are not detected by arrayCGH and not counted by the CNA-index. On the other hand, marker 
chromosomes were counted only as one aberration in Paper 1 and may contain DNA originating 
from more than one chromosome, while unbalanced rearrangements involving marker 
chromosomes would be detected by the methods applied in Paper 3. Several previous studies 
using various methods for quantification of genomic instability have reported significant 
association between the number of genomic aberrations and inferior survival in FL (Tilly et al, 
1994;Ott et al, 2002;Viardot et al, 2002;d'Amore et al, 2008) and this was confirmed in the  
recent study by the LLMPP cooperation (Bouska et al, 2013).  
Clonal evolution in follicular lymphoma and evidence for a FL progenitor cell 
Examination of copy number profiles and patterns of SHM in sequential FL samples (Paper 3) 
revealed that tumor cell clones in relapse samples are unlikely to be direct descendants of 
tumor cell clones present in preceding samples. Among the 39 cases with multiple biopsies, 36 
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showed changes in copy number profiles and CNA-index with time, consistent with the 
extensive clonal heterogeneity observed in FL (d'Amore et al, 2008). In the majority of cases 
with multiple biopsies (27 of 39) the early and late samples harbored unique as well as common 
copy number aberrations. Nine cases showed acquisition of additional copy number aberrations 
at relapse, while the three remainder cases were without clear changes. Even though there was 
a trend for increasing CNA-index in the late FL samples, several cases showed lower CNA-index 
in samples obtained late in the course of disease. The CNA-index showed a striking variability 
both within individual cases and across the whole set of samples.  The variable CNA-index as 
well as the patterns of unique and shared CNAs, indicate that tumor cell clones present at 
different time points in FL arise by divergent evolution from a common ancestor cell. Other 
studies using karyotypic data, chromosomal CGH data and SNP array data have reported similar 
findings comparing paired samples of primary FL and relapses showing either FL or transformed 
lymphoma (DLBCL) (Johnson et al, 2008;d'Amore et al, 2008;Martinez-Climent et al, 
2003;Fitzgibbon et al, 2007).  
Analysis of the DNA sequence in rearranged IGH loci in a subset of sequential samples 
confirmed a clonal relationship (Paper 3). In addition, the analysis of somatic hypermutations in 
the IGVH region showed that early and late samples harbor unique as well as common SHMs, 
suggesting that tumor cell clones dominating in different serial samples originate from a less-
mutated common ancestor clone. Similar findings were reported in previous studies with 
sequence data from IGV loci and the swicht-region of IGH (Aarts et al, 2001;Bognar et al, 
2005;Adam et al, 2007;Matolcsy et al, 1999;Ruminy et al, 2008;Carlotti et al, 2009).  
Previous studies have addressed the question if genomic aberrations arise by distinct 
evolutionary pathways in FL. In the studies by Høglund et al (Hoglund et al, 2004) and d’Amore 
et al (d'Amore et al, 2008), copy number aberrations were classified as early or late events in 
the pathogenesis of FL. Both studies reported that extra copies of, chromosomes 7, X and 
der(18)t(14;18) as well as loss of chromosomal arm 6q were frequent early events in the 
development of FL. Other aberrations were however, also observed as early events, indicating 
that the evolutionary pathways of FL development are heterogeneous. 
Clonal heterogeneity in FL can also be observed in simultaneously obtained samples 
from a lymph node and other anatomical sites such as the bone marrow or peripheral blood. It 
has been shown that the different tumor cell clones traffic in both directions between 
peripheral nodes and the bone marrow (Ruminy et al, 2008;Aarts et al, 2001;Oeschger et al, 
2002;Wartenberg et al, 2013). It has been proposed that FL originates from a t(14;18) positive 
cell that has entered a reactive germinal center and that FL cells migrate early to the bone 
marrow which may function as a protective niche during chemotherapy (Wartenberg et al, 
2013). 
Recent studies using phosphorylation specific probes and cell sorting of FL cell 
suspensions by flowcytometry have shown that BCR-signaling was not inducible in FL cell clones 
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emerging at relapse as opposed to the potent inducible signaling in FL cells in samples obtained 
prior to treatment. The finding indicates that FL cells may become independent of BCR-signaling 
for survival. These relapse clones were also negative for the B-cell marker CD20 (Irish et al, 
2010). The loss of CD20 expression represents a clinical challenge as it correlates with resistance 
to rituximab treatment (Hiraga et al, 2009). The observed phenotypic changes in signaling 
capacity and surface marker expression are consistent with the clonal diversity in FL.  
Advances in high-throughput sequencing technology have enabled whole exome 
sequencing of FL cell subpopulations. In combination with analyses of SHM of the IGVH, findings 
from deep sequencing confirm that tumor cell subpopulations are genetically divergent and 
support the hypothetical evolution from a common FL progenitor cell. Based on the subclonal 
representation of somatically acquired mutations, early versus late mutational events could be 
identified in FL (Green et al, 2013). Mutations targeting genes encoding histone-modifying 
proteins (EZH2, CREBBP and MLL2) represent early genetic events in the development of FL 
(Morin et al, 2010;Green et al, 2013) and may thus characterize the FL progenitor cell. 
Even though the copy number profiles varied in sequential biopsies, there were only 
small increases in overall CNA frequencies in the latest FL samples compared to the initial 
samples. In Paper 1, FL samples obtained from different patients who had or had not received 
treatment were compared to assess the impact of treatment on genetic evolution. 
Isochromosome 6p and loss of 6q were more frequent in samples from treated patients. A weak 
trend for increasing loss of 6q was also present in samples obtained after treatment in the serial 
biopsies (Paper 3, supplemental figure 1 A). The number of aberrations in samples from treated 
and untreated patients did not differ significantly between the two groups (Paper 1). Results 
from both studies indicate that few systematic changes in aberration frequencies take place in 
the relapse of FL. This is in line with a previous study by d’Amore et al 2008, in which 
cytogenetic data from 418 t(14;18)-positive FL samples originating from 360 patients showed 
that the frequencies of gains and losses were similar in different cell clones.  
While there are small changes in aberration frequencies in primary compared to 
relapsed FL, we observed significant differences comparing samples of DLBCL transformed from 
FL (n=15) with samples of FL grade 1-3a (n=107) in Paper 1. Loss from 14q, monosomy 15, 
trisomy 16 and 22 were more frequent among the transformed samples. The total number of 
aberrations did not differ between the two groups of samples. Other studies comparing 
cytogenetic data from paired samples of FL and samples showing transformed FL (DLBCL) 
indicate that higher-grade transformation is associated with acquisition of a heterogeneous set 
of genomic aberrations. DLBCL samples often have more complex genotypes than the FL 
counterpart and some CNAs are more common in the transformed lymphoma; for instance 
gain/rearrangements of 3q27 (BCL6 locus), gain of 12q, 7q, 18q and Xq and loss of 1p36, 6q, 
9p21, 13q, 17p (Johnson et al, 2008;Martinez-Climent et al, 2003;Nagy et al, 2000;Hough et al, 
2001;Fitzgibbon et al, 2007). 
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The histological grade of FL may change at relapse. Among the 14 patients in Paper 3 
with biopsies showing FL grade 3a, 10 had additional biopsies showing FL grade 1-2. To 
investigate whether or not the shift in histological grade is associated with clonal evolution, we 
compared the frequencies of copy number aberrations in FL grade 1-2 and FL grade 3a (Paper 1 
and 3). We observed a higher incidence of loss from chromosomal arm 1p, including 1p36, in FL 
grade 3a, in line with previous findings (Horsman et al, 2001;Ott et al, 2002). In Paper 3, an 
increased incidence of gain of chromosome 5 in FL grade 3a was especially prominent. Genomic 
instability, as quantified by the CNA-index, was significantly higher in FL grade 3a samples, in 
line with other studies (Horsman et al, 2001;Ott et al, 2002;Mohamed et al, 2001;d'Amore et al, 
2008). In contrast to this, the number of aberrations as counted in Paper 1 was not significantly 
different in FL grade 1-2 and FL grade 3a. Loss of 1p36, the degree of genomic instability and 
grading of FL have all been associated with prognosis in FL, suggesting that FL grade 3a may 
represent a more aggressive presentation of FL (Lestou et al, 2003) and others). On the other 
hand, results from other studies contradict a prognostic significance of FL grade (Shustik et al, 
2011) and references therein). The clinical significance of FL grading may however, depend on 
treatment as a recent study by Whalin et al (Wahlin et al, 2013) show better overall survival in 
patients with FL grade 3a than in grade 1-2 when treated with rituximab monotherapy.   
In summary, there are several lines of evidence for a parallel evolution of tumor cell 
clones in FL. We have shown that clonal evolution in FL is traceable at a whole genome level as 
well as by the mutational patterns of the IGH locus. Our findings confirmed that parallel 
evolution of tumor cell clones contribute to genetic diversification in FL and support the 
hypothesis of a FL progenitor cell. One may speculate that slowly proliferating FL progenitor 
cells escape chemotherapy treatment and give rise to relapse. Parallel evolution and trafficking 
of tumor cell clones explains how genetically different tumor clones may dominate at different 
times and different anatomical sites creating different morphologic and histologic appearances, 
and showing different interactions with the microenvironment, different proliferation capacity 
and different treatment sensitivity. Clonal heterogeneity in time and space may account for the 
different results reported in studies of associations between genetic aberrations and patient 
outcome in FL. Nevertheless, we and others have shown that specific secondary aberrations are 
significantly associated with the risk of transformation and/or with inferior survival. One may 
speculate that these aberrations, upon appearance, endow tumor cells with the propensity to 
transform and/or resist treatment. The existence of a FL progenitor cell has implications for the 
development of new treatment strategies in FL. In order to be curative, a treatment needs to 
combine drugs targeting features of the FL progenitor cells with drugs targeting derived 
subclones which may be present simultaneously. To try characterizing the FL progenitor cell 
more closely, it would be interesting to perform whole-genome deep sequencing as well as high 
resolution assessment of DNA copy number in new patient cohort with serial FL samples. 
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Gene dosage effect in FL and identification of cancer driver genes  
In Paper 4, we showed that gene expression levels correlate positively with DNA copy number 
levels for a majority of genes within aberrant regions, indicating that a gene dosage effect 
deregulate transcription in FL. Applying strict selection criteria we singled out 698 genes 
showing a high correlation between gene expression and copy number (cis-genes).  
Previous integrative analyses of gene expression and copy number data in for instance 
DLBCL, mantle cell lymphoma and other cancers such as breast cancer, proved the presence of a 
gene dosage effect in tumors with chromosomal imbalances. Closer examinations of the genes 
that are subject to gene dosage effect have identified key drivers of oncogenesis (Lenz et al, 
2008c;Hartmann et al, 2010;Pollack et al, 2002;Akavia et al, 2010).  
In FL, few integrative analyses of gene expression and copy number profiling have been 
performed (Martinez-Climent et al, 2003;Schwaenen et al, 2009;Leich et al, 2009). The studies 
report that low proportions of genes within aberrant genomic regions show consistent 
expression levels. The number of cis-genes identified in our study is also low considering the 
large genomic regions that are recurrently targeted by gains and losses in FL. High level 
amplifications are rarely seen in FL. Thus the gene dosage effect may be more subtle in FL than 
in cancers with higher degrees of genomic instability. Importantly, FL samples contain variable 
amounts of T-cells, macrophages, endothelial cells and fibroblasts in addition to the malignant 
B-cells. The signals from these normal cells attenuate signals from malignant B-cells in arrayCHG 
analyses and create “biological noise” in gene expression analyses. Indeed, gene expression 
profiles of tumor infiltrating immune cells rather than that of FL cells predicted patient outcome 
in the landmark study by Dave SS et al (Dave et al, 2004). The tumor specific molecular 
mechanisms behind progression and transformation of FL may on the other hand be masked by 
the effect of the microenvironment. 
As copy number alterations are specific for the malignant B-cells in FL, the 698 cis-genes 
are likely to represent tumor specific transcriptional activity. In addition, the recurrent copy 
number aberrations are likely to represent genetic alterations of selective advantage for the 
lymphoma cells. We thus hypothesized that these genes may be of importance for the 
development and progression of follicular lymphoma.  
The study by Martinez-Climent included expression and copy number data paired 
samples of FL and DLBCL originating from 10 patients. The findings were too heterogeneous to 
make a comprehensible comparison to the results presented in Paper 4. Both Schwaenen et al 
(2009) and Leich et at (2009) report similar patterns of recurrent genomic gains and losses as we 
do in Paper 3. In the study by Schwaenen et al (2009) expression levels of only 28 annotated 
genes located in consensus regions of gains or losses were reported to be significantly 
correlated to copy number. Nine of these (32%) were also present in the list of 698 cis-genes 
(MAP3K7, SNX3, KIAA0274/FIG4, CRSP3/MED23, VNN2, TBPL1, FLJ11712/RNASEH2B, ACAA2 
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and SMAD2). The study does not report data from chromosome X where a majority (23%) of cis-
genes were located. In Leich et al (2009) the frequencies of aberrations are lower than in our 
data set, probably due to the lower resolution of conventional CGH compared to array CGH. 
Leich et al (2009) reported significant associations between gene expression and copy number 
levels for 2465 probe sets located within 195 minimally altered chromosomal regions. This data 
set was used for validation of our findings. Interestingly, most of the 698 cis-genes identified in 
Paper 4, also show high, positive correlations between expression and copy number in the Leich 
data set. 
The molecular network most significantly enriched for cis-genes contained genes 
associated with B-cell receptor- and Toll like receptor-signaling including mediators and 
regulators in the NF-kB pathway. The pathway analysis indicated that expression levels of 14 
genes that are involved in NF-kB-activation are influenced by copy number in FL. For these 14 
genes, we identified a subset of correlated NF-kB target genes and these were used to calculate 
a corresponding gene expression score.  For six of these genes (BTK, IGBP1, IRAK1, ROCK1, 
TMED7-TICAM2 and TRIM37) the scores were significantly associated with transformation of FL.  
The protein encoded by IRAK1 mediates Toll- like receptor (TLR) signaling down-stream 
of the adaptor protein MyD88. TLRs recognize pathogen-associated molecular patterns (PAMPs) 
such as bacterial lipopolysaccharides (TLR4), bacterial flagellin (TLR5), viral double stranded RNA 
(TLR3), as well as bacterial or viral unmethylated CpG containing DNA (TLR9) and single stranded 
RNA (TLRs 7 and 8). Endogenous substances released at cellular stress and tissue destruction (i.e 
heat shock proteins and fibronectin) may also activate TRLs. Down-stream effects of TLR 
signaling include activation of transcription factors NF-kB, AP-1 and IRFs. Their role in initiation 
of the innate immune response is well described (Janeway CA, 2005). TLRs are expressed on 
both B- and T lymphocytes and modulate the adaptive immune responses. In a study by Ngo VN 
et al (2011) it was shown that 30% ABC-DLBCL cases harbor activating MyD88 mutations that 
promote constitutive NF-kB activation. This finding has contributed to an expanding research 
focusing on TLR-singaling in B-cell malignancies (Chiron et al, 2008;Harsini et al, 2013).  
TRIM37 encodes a ubiqutinin ligase in the TRIM-familiy which compises several proto-
oncogenes (ref). To the best of our knowledge, the role of TRIM37 in lymphocytes or lymphoma 
has not been investigated. Interestingly, a combination of the NF-kB target gene scores for 
IRAK1 and TRIM37 resulted in the best separation of FL cases with and without transformation.  
The probe for TMED7-TICAM2 represents a read through transcription of the 
neighboring genes TMED7 and TICAM2. Several splice variants of the transcript exist. TICAM2 
encodes an adaptor molecule down-stream of TLR4 and mediates NF-kB activation (also known 
as TRAM)(refs as above), while the protein TMED7 has been shown to inhibit TLR4 signaling 
(Doyle et al, 2012). Further investigation is needed to determine the splice variants that are 
present in FL and what role the different variants may play in promoting transformation.  
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The kinase BTK is activated by BCR-signaling and mediates NF-kB activation. There is 
substantial evidence for involvement of BCR-signaling in the pathogenesis of ABC-DLBCL, 
marginal zone lymphoma, chronic lymphatic leukemia (CLL) and Burkitt’s lymphoma (Young & 
Staudt, 2013). Although several observations indicate a role of BCR in FL-pathogenesis, the exact 
mechanisms for BCR-involvement are poorly understood. FL invariably express BCR and even 
cases relapsing after anti-idiotype antibody treatment are BCR-positive, indicating involvement 
of BCR in development and survival FL cells. The translocation t(14;18) always involves the 
unproductive IgH allele which may be isotype switched, while the productive allele remains IgM, 
indicating that sustained IgM surface expression is of importance for FL cells (Young & Staudt, 
2013;Kuppers, 2005). In flowcytometry studies using probes specific for phosphorylated 
molecules, inducible BCR-signaling was more potent in FL B-cells than in normal B-cells. 
However, in FL cell clones emerging at relapse, BCR-signaling was not inducible, indicating an 
acquired independency of BCR-signaling for FL cell survival (Irish et al, 2010). Nevertheless, 
signaling in the pathways regulating B-cell proliferation may be maintained by other 
mechanisms working downstream of the BCR. It would be interesting to study closer the 
consequences of BTK over-expression or knock-out for signaling, survival and proliferation of FL-
cells. Whether or not the higher expression score of the associated NF-kB target genes results 
from BTK over-expression needs to be further investigated. Recent clinical trials support a role 
of BTK in FL and other B-cell malignancies; treatment with ibrutinib, a BTK-inhibitor, induces 
remission in patients with relapsed and refractory B-cell malignancies, including follicular 
lymphoma (Advani et al, 2013).  
The protein IGBP1 was first found to be associated with the CD79a subunit of the B-cell 
receptor (Inui et al, 1995) and later also identified as a broadly expressed regulatory subunit of 
protein phosphatase 2A (Chuang et al, 2000). Over-expression of IGBP1 is associated with 
inferior outcome of small cell lung carcinoma, which may indicate that its role as an oncogene is 
independent of its role in BCR-signaling in lymphoma (Sakashita et al, 2011). Whether the role 
for IGBP1 in transformation of FL is associated with activation of NF-kB or other oncogenetic 
pathways needs to be further investigated. 
 ROCK1 encodes a protein kinase with ubiquitous tissue distribution. It is known to 
regulate cellular adhesion, migration and invasion. ROCK1 has been shown to be over-expressed 
in cancer and associated with metastasis and inferior outcome. To the best of our knowledge, a 
role in B-cells or lymphoma has not been investigated (Patel et al, 2013). 
The average expression of all NF-kB target genes was not associated with 
transformation. Comparison of the average transcription level of NF-kB target genes across 
subtypes of B-cell lymphoma showed lower levels in FL than in DLBCL, and especially compared 
to the ABC subtype in which NF-kB signaling is constitutive active. Whether or not the subsets of 
NF-kB target genes that predicted transformation reflects a general NF-kB activation in FL is 
uncertain. One may speculate that NF-kB activation takes place in a subclone of FL and that the 
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gene expression signals produced from such a subclone is partly masked by other FL clones as 
well as by the bystander T-cells and macrophages. It is also possible that the activation of NF-kB 
target gene subsets is due to the action of other transcription factors with partially overlapping 
target gene sets. 
The molecular mechanisms underlying transformation from FL to DLBCL have been 
studied by comparing tumor samples before and after transformation using various methods 
(reviewed in (Bernstein & Burack, 2009) and others). Elevated expression of c-MYC and other 
genes promoting proliferation, inactivation of TP53 and CDKN2A, dysregulation of p38-MAPK, 
mutations of BCL6 and composition of the tumor microenvironment have all been implicated in 
subsets of cases with transformation (Elenitoba-Johnson et al, 1998;Lossos et al, 2002;Martinez-
Climent et al, 2003;Akasaka et al, 2003;Elenitoba-Johnson et al, 2003;Davies et al, 2005;Davies 
et al, 2007;Glas et al, 2007). More recently, an expression signature (LPS score) has been shown 
to predict transformation and survival in FL (Gentles et al, 2009). The LPS is derived from three 
gene modules; two modules with genes typically expressed in embryonic stem cells and one 
stromal cell module. The LPS score did not predict transformation in our data set. This may be 
due to the lower number of patients in our study than in Gentles et al. On the other hand, 
higher expression of the MYC-signature as defined by Lossos et al (2002) in tumor samples (FL 
and DLBCL) was significantly associated with transformation in our data set. Then again, the 
MYC-signature score in FL-samples did not predict transformation in our data set, indicating that 
increased expression of the MYC-signature reflects increased proliferation in transformed 
tumors rather than being the cause of transformation. 
In Paper 4, we showed that transformation can be predicted based on the expression 
level of subsets of NF-kB target genes in biopsies showing FL. Of note, a high signature score 
was found in FL samples preceding transformation, but not always in the diagnostic specimen. 
This is in line with the clonal evolution and heterogeneity observed in FL. The prediction of 
transformation based on molecular features in FL samples will thus require a liberal practice for 
performing biopsies. 
In future projects, we will seek to validate the predictive significance of the NF-kB target 
gene signatures in a patient cohort treated in the rituximab era. A recent study from the 
University of Iowa/Mayo Clinic, reports reduced transformation rates in the present treatment 
era (Link et al, 2013). Thus, studies of risk factors for outcome in FL will require prolonged 
observation times and larger patient cohorts. Results from such a study may then motivate the 
development of a test to assess transformation risk.  
It would also be of interest to examine closer the functional role of some of the cis-genes 
follicular lymphoma; especially BTK, IGBP1, IRAK1, ROCK1, TMED7-TICAM2 and TRIM37, in order 
to identify new treatment targets in FL.  
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